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Eight genetically distinct serotypes (A-H) of Botulinum neurotoxin (BoNT) cause flaccid 
muscular paralysis through inhibition of neurotransmission at cholinergic nerve terminals. 
BoNT binds with specificity to the neuromuscular junction and enters through endocytosis. It 
translocates its catalytic moiety through the endosomal membrane into the cell cytosol and 
finally proteolyses soluble N-ethylmaleimide-sensitive-factor attachment protein receptors 
(SNAREs) inside the neuromuscular junction, thereby preventing synaptic vesicle fusion with 
the plasma membrane. The action of BoNT is facilitated by its tri-domain structure which 
includes: the receptor binding domain (HC), the translocation domain (HN) and the catalytic 
domain (LC). Removal of BoNT’s HC domain leaves a stable, catalytically active molecule 
(LHN), which lacks specificity for the neuromuscular junction. The least understood step in 
the mechanism of BoNT action is the translocation of the LC domain through the endosomal 
membrane into the cell cytosol; this action is thought to be preceded by the formation of an 
HN domain pore following acidification of the endosomal compartment. In this study we set 
out to investigate this step. We investigated the interaction of BoNT and LHN proteins with 
cellular and artificial membranes. Firstly, the interaction of LHN serotype D (LHD) with 
Chinese Hamster Ovary cells (CHO-K1 cells) was investigated by measuring an apparent LHD 
induced increase in CHO-K1 cell intracellular Ca2+ levels. The increase was affected by 
extracellular Ca2+ concentration suggesting that LHD may permeabilise the membrane of 
CHO-K1 cells at near neutral pH. Secondly, we developed novel expression and purification 
methods for BoNT HN domains (serotypes A, C and D). This allowed us to compare the 
lipophilicity of the HN domains from multiple serotypes, further supporting a role for this 
domain as a pore forming moiety. Thirdly, vesicle leakage assays were explored as a method 
for determining protein or peptide pore formation in an attempt to further define the pore 
forming potential of BoNT and LHN proteins of various serotypes. However, in these 
experiments, control proteins with no known pore forming ability also caused vesicle 
leakage at acidic pH; the ability of a vesicle leakage assay to sufficiently demonstrate protein 
or peptide pore formation has not therefore been confirmed in this study. Investigation into 
LHN and BoNT induced pore formation in lipid vesicles via electron microscopy was similarly 
inconclusive. Together the results presented in this thesis show that the HN region of BoNT 
serotypes A, C and D can be purified as isolated lipophilic domains, furthermore, the 
interaction of BoNT constructs containing the HN domain with membranes is consistent with 
a function in transmembrane protein translocation.  
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1 Introduction  
1.1 Bacterial toxigenesis 
 
 In 1676 Antonie Van Leeuwenhoek peered down a single lens microscope and 
observed small organisms which he termed “Animalcules”. Following initial scepticism, his 
observations were confirmed by Robert Hooke of the Royal Society of London after 
repetition of the experiment. Unwittingly, Leeuwenhoek had just made undoubtedly one of 
the most important discoveries in science; he had discovered “Bacteria” (Dobell, 1923; 
Fred, 1933). 
 
 Engaged by the idea of microbiology, Louis Pasteur established fermentation to be 
as a result of micro-biological growth (1859). This led Pasteur and his contemporary Robert 
Koch to both subscribe to “the germ theory of disease”, here they hypothesised that 
bacterial organisms were responsible for certain diseases. Robert Koch developed the idea 
of germ theory through pioneering work on cholera, anthrax and tuberculosis culminating 
in his proof of germ theory for which he was awarded the Nobel prize in 1905. “Koch’s 
postulates”, the criteria with which he determined an organisms potential to cause disease 
are still used today (Inglis, 2007). 
 
 Pioneering work by Koch and Loeffler alluded to the anticipated release of toxic 
molecules by bacteria as a mechanism for the proliferation of some diseases including 
cholera (Vibrio cholerae) and diphtheria (Corynebacterium diphtheriae). Today we define 
this process as bacterial toxigenesis. 
 
 There are two main types of bacterial toxigenesis; cell associated toxins known as 
endotoxins and extracellular diffusible toxins known as exotoxins. Endotoxins are structural 
components of the bacteria, specifically lipopolysaccharides (LPS) or lipoligosaccharides 
(LOS) located on the outer membrane of Gram-negative bacteria. Exotoxins are 
predominantly secreted by bacteria but may also be released following cell lysis (Rietschel 
et al., 1994). Exotoxins are predominantly proteins or peptides, when these molecules 
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interact with a host’s cellular environment they elicit specific host responses (Turton et al., 
2002). 
 
1.2 Diversity of bacterial exotoxins 
 
 Most bacteria capable of producing disease causing exotoxins produce a species 
specific toxin (e.g. Clostridium tetani produces tetanus toxin which causes tetanus and 
Corynebacterium diphtheria produces the diphtheria toxin which causes diphtheria) (Hoch 
et al., 1985). This is not true for all species of exotoxin, some can be produced by multiple 
species of bacteria (e.g Clostridium botulinum, Clostridium butyricum, Clostridium baratii 
and Clostridium argentinense produce botulinum toxin which in turn causes Botulism). The 
associated exotoxins are normally produced in the exponential phase of bacterial growth 
(Montal, 2010).  
 
 Diversity in bacterial toxins can be seen clearly by distinct differences in their site of 
action, mechanism of action, potency, size and structure (Table 1-1). Descriptive pre-
cursors such as enterotoxin, neurotoxin, leukocidin and haemolysin indicate in generality 
the sites targeted by the proteins. Enterotoxins, such as cholera enterotoxin (produced by 
Vibro cholera), target the gastrointestinal tract, a common symptom of which is severe 
diarrhoea and vomiting (de Haan and Hirst, 2000); neurotoxins such as botulinum 
neurotoxin and tetanus neurotoxin target the nervous system, the details of which are 
discussed in detail below; leukocidin’s, such as Panton-Valentine leukocidin (produced by 
Staphylococcus aureus), are pore forming toxins originally discovered due to their ability to 
cause leukocyte cytosis (Kaneko and Kamio, 2004); haemolysin toxins, such as alpha-
haemolysin (also produced by Staphylococcus aureus), are pore forming toxins capable of 
causing cell lysis through uncontrolled permeation of water ions and small organic 
molecules, they were originally discovered through monitoring their ability to cause red 
blood cell cytosis (Gouaux et al., 1997). Toxins without known mechanisms which cause 
animal death are simply known as lethal toxins. Some toxins, known as invasins, have a less 
specific site of action and the ability to enable bacterial invasion through breaking down 





Figure 1-1 The molecular organization of AB toxins during subunit A translocation   




1.3 A plus B subunit arrangement 
 
 Many toxins which act at specific intracellular sites adhere to a two domain 
structure consisting of subunits A and B: subunit A is the catalytically active element, and 
subunit B is responsible for cell specificity, binding and subunit A translocation (Odumosu et 
al., 2010). 
 
 The A and B subunits are synthesised and arranged in a way which is species 
dependent. A + B toxins subunits are synthesised separately and eventually interact at the 
target cell to create a viable toxin (e.g. Bacillus anthracis EF, Anthrax toxin LF); A-B or A-5B 
refer to A and B subunits synthesised separately and associated by non-covalent bonds 
during secretion (e.g. Cholera toxin, Pertussis toxin and E.coli heat-labile toxin LT); 5B refers 
to a pentameric arrangement of the binding and translocation region. A/B toxins are 
synthesised as a single unit which is separated by proteolytic cleavage (e.g. Botulinum 
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Table 1-1 A small selection of genetically diverse AB exotoxins  
This table demonstrates the diversity of known AB toxins by highlighting difference 
between their respective catalytic action, subunit organization and receptor binding. 




 Once synthesised there are two prominent ways in which toxins are thought to 
enter host/target cells, namely direct entry and receptor mediated endocytosis. Direct 
entry is a mechanism by which the toxins B domain forms a pore in the target cell 
membrane allowing the A subunit to enter the cytosol of the target cell directly from the 
cell exterior (Balfanz et al., 1996).  Receptor-mediated endocytosis requires the binding of 
subunit B to the target cell exterior followed by the internalisation of subunits A and B 
within an endosome. Finally the B subunit permeates the endosomal membrane permitting 




 The genus Clostridium consists of large, Gram-positive, rod-shaped bacteria within 
the phylum Firmicutes. There are over 100 species of clostridia characterised by 16s RNA 
sequencing, all species form endospores and only grow under anaerobic conditions; 
however, the spores generated by clostridia can survive long periods in aerobic conditions. 
Clostridia will grow in virtually all anaerobic habitats where organic compounds are present, 
including soils, aquatic sediments and the intestinal tracts of mammalian organisms 
(Coffield et al., 1994; Shukla and Sharma, 2005). 
 
 Through fermenting a large range of organic compounds, clostridia produce waste 
compounds such as butyric acid, acetic acid, butanol, acetone, carbon dioxide and 
hydrogen. The bacteria secrete a variety of extracellular enzymes which degrade biological 
molecules including proteins, lipids, collagen and cellulose. Consequently Clostridia is 
known to play an important role in the carbon cycle (Wang et al., 2013). In Clostridia 
infection, the ability to degrade large biological molecules can play a role in invasion and 
pathology. Some species of the clostridia are pathogenic for humans, primarily Clostridium 
perfringens, C. difficile, C. botulinum and C. tetani produce the most toxic biological 
molecules known to man (Maclennan, 1962; Shukla and Sharma, 2005). 
 
 Tetanus is caused by C. tetani exotoxins known as tetanus neurotoxin (TeNT) or 
tetanospasmin. TeNT targets the central nervous system through inhibiting 
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neurotransmission leading to potentially fatal spastic paralysis. The toxin binds to 
cholinergic motor neurones where it is subjected to retrograde axonal transport to spinal 
cord neurones.  Neurotransmission is inhibited through TeNT’s cleavage of synaptobrevin 
preventing cellular secretion. The structure and mechanism of action of TeNT is very similar 
to that of Botulinum toxins (see below) (Shukla and Sharma, 2005).  
 
1.4 Botulinum neurotoxins and Botulism 
 
 Botulism is a rare but severe paralytic disease caused by an exotoxin produced by 
the bacterial species Clostridium botulinum, Clostridium butyricum, Clostridium baratii and 
Clostridium argentinense, namely, Botulinum neurotoxin (BoNT). Justinus Kerner first 
described Botulism in the 19th century following a severe food poisoning outbreak that was 
traced back to the ingestion of blood sausage; consequently, the name Botulinum was 
derived from the Latin term for sausage (botulus) (Hatheway, 1990). 
 
 Through a mechanism which will be discussed in detail, BoNTs cause muscular 
paralysis by inhibiting synaptic action and consequently nerve signal transmission at the 
neuromuscular junction. Portals for BoNT entry into the circulatory system include the 
pulmonary tract (inhalation botulism), the gastrointestinal tract (food-borne and infant 
botulism) and through the broken skin of wounds (wound botulism). Regardless of the 
route of infection, if BoNT enters the circulatory system and is transported to the 
neuromuscular junction of motor neurones, it has the potential of inhibiting muscle 
contraction (Montal, 2010). 
 
 The clinical hallmark of botulism is an acute flaccid paralysis which begins with 
bilateral cranial nerve impairment, involving muscles of the eyes, face, head and pharynx 
and then descends symmetrically to involve muscles of the thorax and extremities. 
Symptoms which characterise the disease include blurred vision, amblyopia, ptosis and 
photophobia which can be followed by signs of bulbar nerve dysfunction such as dysarthria, 
dysphonia and dysphagia. However, early symptoms are mostly non-specific and difficult to 
distinguish from the over indulgence of alcohol. If Botulism has been contracted from food 
borne bacteria, initial symptoms may include nausea, abdominal pain and diarrhoea, most 
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likely caused by other bacterial exotoxins, before any sign of neurologic complication 
develops (Caya et al., 2004). 
 
 If the disease is allowed to progress without treatment, death may result from 
respiratory failure caused by paralysis of the tongue or muscles in the pharynx causing 
upper airway occlusion or via paralysis of the diaphragm and intercostals muscles. The 
severity, rate and duration of Botulism is dependent on the serotype specific action of BoNT 
and the dose of toxin (Peck, 2009). 
 
 Due to its potency and its potential to cause death through muscular paralysis, 
BoNT has be classified as the most deadly toxin known to mankind and consequently as a 
“select agent” meaning criminal prosecution for those who do not follow strict government 
guidelines regarding obtaining, handling and documenting its use.  Due to its relative ease 
of production and virulent potential through aerosol, BoNT’s have concurrently been 
determined a category A biological weapon by the Centres for Disease Control and 
prevention (CDC), USA. Assuming a 70kg human, death from BoNT toxicity takes just 0.09-
0.15 µg when injected, 0.7-0.9 µg when inhaled and 70 µg if ingested. Consequentially 1g of 
the toxin has the potential to kill approximately 14,000 people if ingested, 1.25 million if 
inhaled and 8.3 million if injected (Scott and Suzuki, 1988). 
 
1.4.1 The eight serotypes of botulinum neurotoxin 
 
 It became apparent that more than one type of Botulinum toxin existed when 
antitoxin serums, developed to treat Botulism, only proved successful in select outbreaks of 
the disease (Hatheway, 1990). As the new strains of BoNT were discovered they were 
labelled chronologically from serotype A (the first serotype to be discovered) to serotype H 
(the last serotype to be discovered) (Aoki and Guyer, 2001). Variants or subtypes within 
BoNT serotypes A, B, E and F have been designated by adding an Arabic number to the 
toxin type, e.g., A1, A2. 
 
 Botulinum neurotoxins (BoNTs) are produced by at least four diverse groups of 
Gram positive spore-forming anaerobic bacteria under the taxonomic label of Clostridium 
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botulinum (Hedeland et al., 2011). The only criterion for belonging to the C. botulinum 
species is the ability to produce the exotoxin BoNT. Therefore C. botulinum arguably 
encompasses four separate species of bacteria that can be clearly separated into four 
distinct groups (Groups I-IV) via phylogenetic analysis of 16S rrn genes (Hill et al., 2009). 
Group I contains proteolytic serotype A, B and F strains as well as strains that produce two 
botulinum toxin types (bivalent) including Ab, Ba, Af and Bf strains; Group II consists of 
nonproteolytic (np) and saccharolytic serotype B, E, and F strains; Group III consists of 
serotype C and D strains; group IV consists solely of serotype G strains; Group IV has been 
recognised as a distinct species and has been given the name C. argentinense. It has been 
suggested that Groups V and VI should extend to BoNT producing clostridial species such as 
C. baratii (produces BoNT serotype F) and C. butyricum (produces BoNT serotype E) 
respectively (Hill et al., 2009).  
 
 Each serotype of BoNT is encoded by a ~3.8kb gene which is associated with 
accessory genes or predicted open reading frames (orfs) that are collectively referred to as 
the BoNT gene cluster. The BoNT gene cluster includes nontoxic and nonhemagglutinin 
genes and several other genes that encode toxin-associated proteins (hemagglutinins HA-
17, HA-33, HA-70 and p21, and/or p47) (Kubota et al., 1998). There are two types of BoNT 
gene clusters known: the hemagglutinin (ha) toxin gene cluster is found within strains that 
produce toxin types A1, A5, B, C, D and G and the orfX gene cluster is found in strains that 
produce toxin types A1, A2, A3, A4, E and F and in Clostridium butyricum type E and 
Clostridium baratii type F strains. The location of gene clusters encoding BoNT proteins 
varies between serotypes; the genes encoding for BoNT serotypes A, B, E and F are located 
on bacterial chromosomes, BoNT serotypes C and D are encoded for on a phage genome 
and BoNT serotype G is located on a plasmid (Hill et al., 2007). Very recently a new serotype 
of BoNT was discovered and named serotype H, it was found to be located in the orfX toxin 
gene cluster at a unique chromosomal site different from those used by other botulinum 
toxin gene clusters (Barash and Arnon, 2014). 
 
 Comparison of the protein sequences of BoNT serotypes A-G shows that serotype 
identity ranges from 34%-64% (Hill et al., 2009). This variation in serotype diversity is 
thought to be as a result of BoNT genes being horizontally transferred between various 
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clostridial lineages, resulting in the isolated evolution of each BoNT serotype (Hill et al., 
2009). In addition, recombination events within BoNT genes have resulted in mosaic 
serotypes (e.g. BoNT serotypes C/D and A1/A3) which contribute even further to BoNT 
diversity (Hill et al., 2009). 
 
 All BoNT serotypes (A, B, C1, D, E, F, G and H) cause the potentially fatal 
neuroparalytic disease known as Botulism. Only four of the seven serotypes (A, B, E and F) 
have been confirmed to cause naturally occurring human botulism, but seven cause 
inhalational botulism in primates (A-G). There is evidence for the ingestion of serotype C1 
causing human botulism but recent results show serotype D to be largely ineffective in 
humans (Collins and East, 1998; Eleopra et al., 2013). As the clinical uses of BoNT expand, it 
has become more important to understand the differences between BoNT serotypes. 
Although all BoNT molecules are known to inhibit acetylcholine release, they bind to 
different extracellular receptors, act through different intracellular protein targets, exhibit 
different durations of effect and have different potencies (Montal, 2010). 
  
   
1.4.2 The tri-modular architecture of botulinum neurotoxin 
 
 All seven serotypes of BoNT are known to be synthesised as single chain 
polypeptide precursor molecules with approximate masses of 150KDa. The inactive 
precursor protein is post-translationally cleaved (or activated) into two sections, either by 
Clostridial or tissue proteases. The two sections, called the heavy chain (HC) and the light 
chain (LC), create a A-B toxin motif (Figure 1-2). The heavy chain is the larger of the two 
sections with a molecular weight of ~100KDa. It is attached to the ~50KDa light chain 
section via a disulphide bond, hydrogen bonding and Van der Waals interactions. Structural 
elucidation of the toxin has identified that the HC structure is further divided into at least 
two covalently linked domains, namely, the receptor binding domain (HC) and the 




Figure 1-2 Domain organization of Botulinum neurotoxins 
There are three domains present in all BoNT molecules, namely, the receptor binding 
domain (HC), the translocation domain (HN) and the catalytic domain (LC). Following post 
synthetic cleavage these three domains are organized into a 100KDa heavy chain 
(containing the HC and HN domains) and a 50KDa light chain (containing the LC domain). The 
light chain is joined to the heavy chain via a disulphide bond and many intermolecular 
interactions. 
 
 The three domains of BoNT have been determined functionally and structurally to 
be common in seven BoNT serotypes (A-G) and are presumed to be present in the recently 
discovered H serotype (Barash and Arnon, 2014). This tri-modular architecture allows BoNT 
to inhibit the release of acetylcholine from neuromuscular synapses, ultimately causing 
flaccid muscular paralysis. Each domain has a specific role in BoNT’s mechanism of action: 
In general, the HC domain binds specifically to the pre-synaptic membrane of a 
neuromuscular synapse (see section 1.5.1); BoNT is endocytosed into recycling vesicles 
where the acidic environment provokes a conformational change (see 1.5.2.5) and 
ultimately translocation of the LC domain into the cell cytosol through a pore formed by the 
HN domain (see section 1.5.2.4); once inside the cell cytosol the LC domain cleaves soluble 
N-ethyl-maleimide sensitive fusion protein attachment receptor (SNARE) proteins (see 
section 1.5.3). The general and serotype specific function of each domain will be discussed 





Figure 1-3 The tri-modular domain of BoNT is represented in all seven serotypes 
The crystal structures of BoNTA (3BTA), BoNTB (1EPW) and BoNTE (3FFZ) all conform to a tri-
modular architecture; the three domains highlighted are the receptor binding domain (HC) 
(red), the translocation domain (HN) (green) and the catalytic domain (LC) (blue). The three 
domains of BoNTB (1EPW) have been separated and defined (Kumaran et al., 2009; Lacy et 
al., 1998; Swaminathan and Eswaramoorthy, 2000). 
 
1.5 Botulinum neurotoxin mechanism of action 
 
 In order to inhibit neuromuscular communication, botulinum neurotoxin must 
target, infiltrate and disrupt the action of neuromuscular synapses. To understand how one 
molecule can complete all of these tasks, the physiological representation of BoNT’s tri-
modular organisation is assessed with relation to the molecules physical properties and 





Figure 1-4 Mode of action of botulinum neurotoxins.  
Reproduced from (Turton et al., 2002). A four-step mechanism, (1) cell binding, (2) 
endocytosis, (3) translocation of LC in the cytosol, (4) LC cleavage of one of the SNARE 
proteins. (Ach, acetylcholine; AChR, acetylcholine receptor). 
 
1.5.1 Receptor binding 
 
 As discussed, the binding of BoNT’s HC domain to the neuromuscular junction is the 
first step required for intoxication.  BoNTs are known to enter neurones by a dual host 
receptor mechanism which either requires binding to two ganglioside receptors or binding 
to a ganglioside receptor and a synaptic vesicle (SV) associated protein receptor (Benson et 




 Gangliosides are glycosphingolipids which have a ceramide component, imbedded 
in the outer layer of the plasma membrane, and a carbohydrate moiety extending into the 
extracellular space (Figure 1-5). The composition of the carbohydrate moiety of complex 
 13 
 
gangliosides includes a sugar backbone consisting of glucose, galactose and N-
acetylgalactosamine with attached sialic acids to varying degrees and positions (Lopez and 
Schnaar 2009).   
 
 
Figure 1-5 Structure of the GT1b ganglioside 
BoNT serotypes A, B, C, E and G have affinity for the GT1b ganglioside which is found on the 
pre-synaptic terminal of neuromuscular synapses. (Lopez and Schnaar, 2009) 
 
 The abundance of gangliosides on the surface of presynaptic membranes lead to an 
investigation which aimed to determine whether or not they interacted with BoNT 
molecules. Through this investigation it was demonstrated that members of the G1b class 
of ganglioside (specifically GT1b (trisialo gangliosides) and GD1b (disialo gangliosides)) have 
a high affinity for BoNT (Montecucco, 1986). In an effort to further determine the 
importance of gangliosides in BoNTs mechanism of action, monoclonal antibodies specific 
to the GT1b ganglioside were introduced to rat brain synaptosomes, eliminating the toxicity 
of BoNTA and BoNTB respectively (Kozaki et al., 1998). Furthermore, it was demonstrated 
that gangliosides were essential to the binding of BoNTA to ganglioside-deficient murine or 
human neuronal cells (Yowler et al., 2002).   
   
 As its name suggests, BoNTs receptor binding domain (HC) is responsible for the 
binding of ganglioside receptors (Swaminathan, 2011). The binding of gangliosides has been 
demonstrated to be serotype specific. BoNT serotypes A, B, C and F bind to gangliosides 
GT1b, GD1b and GD1a; serotype E binds to GT1b and GD1a; and serotype G recognises all 
gangliosides with similar affinity (Montal, 2010). Recently it has been demonstrated that 
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BoNT serotypes C and D have the potential to simultaneously bind to two ganglioside 
receptors. BoNTC endocytosis requires dual ganglioside binding facilitated by two separate 
binding sites known to have affinity for GD1b and either GD1a or GT1b receptors 
respectively (Karalewitz et al., 2012). Mutagenesis studies of the HC domain of BoNTC and 
BoNTD have shown the toxins potential to bind two ganglioside receptors at separate sites 
including GM3, GM2 GM1 and GDa1 (Strotmeier et al., 2010). Neither of these observations 
precludes BoNT serotypes C and D from concurrently binding proteinous receptors 
although it is likely that their affinity for more than one ganglioside will increase their 
probability of binding to the neuronal cell surface.  
 
Protein receptor binding: 
 
 Ganglioside binding alone does not account for the specificity of most, if not all, 
BoNT serotypes binding to the presynaptic terminal of motor neurones (serotypes C and D 
are possible exceptions as discussed above). After BoNT has bound to gangliosides on the 
neuronal cell surface, a depolarisation event triggers an influx of extracellular Ca2+ which in 
turn promotes the fusion of synaptic vesicles with the neurones plasma membrane, 
exposing luminal domains of synaptic vesicle proteins to the extracellular environment 
(Verderio et al., 2006). Specific luminal domains of synaptic vesicle proteins function as the 
co-receptors for BoNT. When BoNT binds to these co-receptors, it is endocytosed into 
recycling synaptic vesicles (Montecucco, 1986; Zimmermann et al., 1993). Protein receptors 
were found to be key to the BoNT mechanism of action following the discovery that 
treatment of cells with a protease to deplete protein surface receptors protected cells from 
BoNT action (Nishiki et al., 1994). The first synaptic vesicle associated protein receptor 
determined to be essential to the neuronal uptake of BoNT molecules (specifically BoNTB) 
was synaptotagmin (Syt) (Nishiki et al., 1996). BoNT serotypes which share close sequence 
homology within the HC domain recognise the same protein receptors, in summary: BoNTB 
was found to adopt a dual receptor binding complex with synaptotagmin II and GT1b; 
BoNTG was found to require binding to synaptotagmin I or II; and it was found that 
serotypes A, E and F utilise synaptic vesicle protein 2 (SV2) proteins as receptors (Benson et 
al., 2011; Montal, 2010; Peng et al., 2012; Schmitt et al., 2010). The HC domain of BoNTD has 
been shown to have affinity for the SV2 receptor, however the role of this interaction in the 
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mode of action of BoNTD is not clear (Kroken et al., 2011). There is no known protein 
receptor for BoNTC. A crystal structure demonstrating that the HC domain of BoNTB is 
capable of binding Synaptotagmin and GD1a at the same time, has recently been released 
supporting a dual receptor binding model (Berntsson et al., 2013).  
 
 The architecture of the HC domain of BoNT is a well conserved structure throughout 
all seven serotypes (see Figure 1-6). It is composed of two subdomains, N-terminal (HCN) 
and C-terminal (HCC), which are connected by a short helix (Swaminathan, 2011). The crystal 
structure of BoNT serotypes A and B bound to GT1b and synaptotagmin respectively have 
provided evidence that the HCC subdomain is responsible for binding both ganglioside and 
proteinous receptors (Chai et al., 2006; Jin et al., 2006; Stenmark et al., 2008). The two sites 
on the HCC domain include a hydrophobic cavity containing a conserved lactose binding 
motif (H...SXWY...G) separated by a single loop from the protein binding region, which 
contains a hydrophobic pocket within two β-strands (part of a β-trefoil fold). Following the 
elucidation of a crystal structure showing both Syt and GD1a bound to BoNTB it has been 
confirmed that the two respective binding sites do not overlap (Berntsson et al., 2013).  
 
 Although the crystal structures of seven serotypes (A-G) of BoNTs HC domain have 
been solved, the function of the HCN subdomain has still not yet been elucidated. The HCN 
domain adopts a conserved jelly-roll fold typical of lectins and other proteins involved in 
sugar binding and protein interactions. Recent studies have shown its interaction with 
sphingomyelin-enriched membrane micro-domains (Muraro et al., 2009), molecules 
involved in vesicular trafficking (e.g. phosphatidyinositol phosphates (PIPs))  and potential 
binding with PIP binding protein, known to promote diphtheria toxin pore formation 
(Donovan et al., 1982). However, if PIP does play a role in BoNT internalisation and 





Figure 1-6 The BoNT HC domain 
The crystal structures of all seven serotypes of the BoNT HC domain are displayed with PDB 
codes. (Benson et al., 2011; Berntsson et al., 2013; Karalewitz et al., 2010; Kumaran et al., 
2009; Schmitt et al., 2010; Stenmark et al., 2008; Zhang et al., 2010) 
 
1.5.2 Pore formation and light chain translocation 
 
1.5.2.1 BoNT is endocytosed inside synaptic vesicles 
 
 Once BoNT molecules are bound to the pre-synaptic membrane of motor neurones, 
they are endocytosed into synaptic vesicles (see Receptor binding). The evidence for this 
process is substantial including confirmation by immuno-electron microscopy of BoNT in 
synaptic vesicles (Colasante et al., 2013) and the inhibition of BoNT action following the 
proteolysis of BoNT protein receptors known to be recycled within the lumen of synaptic 
vesicles (Nishiki et al., 1994). Following endocytosis, the BoNT molecule is still contained 
within a synaptic vesicle, in order to reach the cell cytosol, BoNT must transfer its catalytic 
LC domain from the synaptic vesicle, through the vesicle membrane and into the cell 
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cytosol (Montal, 2010). This process is undoubtedly the least understood mechanism of 
BoNT action. 
 
1.5.2.2 Synaptic vesicles are acidified 
 
 Once inside synaptic vesicles, BoNT molecules are exposed to the conditions 
imposed by synaptic vesicle recycling, including the acidic environment induced by 
endosomal proton pumps (H+-ATPase’s) (Zimmermann et al., 1993). Inhibition of these 
protein pumps (by bafilomycin) blocks BoNT activity in mouse phrenic nerve-
hemidiaphragm preparations, confirming that the translocation of BoNT’s LC domain into 
the cell cytosol is dependent on exposure of BoNT to an acidic environment (Simpson et al., 
1994).  
 
1.5.2.3 The LC domain of BoNT unfolds under acidic conditions 
 
 Published crystal structures identify the BoNT light chain to be a large globular 
protein approximately 5.5 x 5.5 x 6.2nm in size (Lacy et al., 1998). Due to its large size some 
degree of unfolding is considered to be necessary to facilitate the LC domains translocation 
into the cell cytosol. Indeed, increasing the size of the LC domain and making it more 
resistant to unfolding conditions using anti-LC monoclonal antibody fab fragments was 
found to arrest translocation through excised Neuro 2A membrane fragments (Fischer and 
Montal, 2007b). Furthermore, spectroscopic analysis showed structural changes in the LC 
domain of BoNTA at pH values similar to those found in synaptic vesicles (Koriazova and 
Montal, 2003) and analysis of lipophilic dye binding to solvent exposed hydrophobic 
patches supported the unfolding of the LC domain at acidic pH (Cai et al., 2006). Conflicting 
results have been obtained when using circular dichroism to measure the degree to which 
the fold of the LC domain changes under acidic conditions (Koriazova and Montal, 2003; Li 
and Singh, 2000), this difference of opinion has not been settled, however the crystal 
structure of the LC domain of BoNTB does not appear to be altered for that resolved at near 





   
1.5.2.4  The HN domain of BoNT forms a pore in the synaptic vesicle membrane 
 
 There is relatively little structural information known regarding the HN domain of 
BoNT proteins. However, the crystal structures of holotoxin BoNT serotypes A, B and E have 
been solved providing evidence of a long thin domain consisting of antiparallel and 
amphipathic α-helices (approximately 100Å in length) that form a coiled coil. A shorter α-
helix structure packs in parallel on both sides of the larger helices and a large relatively 
unstructured “belt region” forms a loop which wraps around the LC domain either covering  
or near to the catalytic pocket (BoNTA and BoNTB respectively) (Kumaran et al., 2009; Lacy 
et al., 1998; Swaminathan and Eswaramoorthy, 2000). The HN domains of BoNT serotypes 
C, D, F, G and the newly discovered serotype H are the only BoNT domains not to have been 
solved by X-ray crystallography (excluding subserotypes). 
 
 Acidification of the synaptic vesicle not only causes a structural change in the LC 
domain but simultaneously triggers the insertion of the translocation domain (HN) into the 
synaptic vesicle membrane (Brunger et al., 2007; Galloux et al., 2008; Lai et al., 2010; Shone 
et al., 1987). The protonation of charged groups on the surface of the HN domain (and on 
the HN domain belt region) reduces the molecules electrostatic repulsion from lipophilic 
environments and consequently facilitated HN domain interaction with the phospholipid 
membrane. This observation is supported by an increase in HN domain interaction with 
synthetic lipid vesicles following a decrease in NaCl concentration under acidic conditions 
(Lai et al., 2010). 
 
 The mechanism by which a pore is formed by the HN domain is still elusive. 
Whether or not BoNT forms a multimeric channel is debated by researchers in the field. The 
argument for oligomeric pore formation is compelling; evidence for oligomeric pore 
formation includes (1) a low resolution electron micrograph of the interaction of BoNTB 
with synthetic vesicle membranes showed evidence for a tetrameric “doughnut shaped” 
channel (Schmid et al., 1993) and (2) the GT1b mediated interaction of BoNTB with lipid 
bilayers suggesting an oligomeric pore, seen using atomic force microscopy (Sun et al., 
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2011). The argument against oligomeric pore formation centres around immune-electron 
microscopic observations that only one molecule of BoNT (maximum two) is endocytosed 
per synaptic vesicle; this conclusion is based on counting the number of immune-labelled 
BoNT molecules detected within synaptic vesicles (Pirazzini et al., 2011). 
 
 Further evidence that the HN domain of BoNT forms a pore was provided by the 
electrophysiological analysis of the interaction between holotoxin BoNT molecules and 
BoNT derivatives with cellular membranes. These studies monitor pores formed in excised 
segments of either Neuro 2A or PC12 cellular membranes through measuring the electrical 
current between the side of the membrane exposed to BoNT (called the cis side) and the 
side of the membrane not exposed to BoNT (called the trans side). Through these 
experiments it was determined that conditions at the cis side of the excised membrane 
must be acidic and oxidising, whereas conditions at the trans side must be neutral and 
reducing for BoNT pore formation to occur (Fischer and Montal, 2006; Koriazova and 
Montal, 2003).  Concurrently, the need for acidic pH to trigger BoNT pore formation has 
also been determined in artificial membranes by measuring the leakage of fluorescent or 
charged molecules from within large unilamellar vesicles (LUV’s) (Hoch et al., 1985; Shone 
et al., 1987). Evidence that the HN domain of BoNT may form pores in both cellular and 
synthetic membranes without either the HC or LC domains respectively, has been collected 
using both electrophysiological and vesicle leakage techniques (Fischer and Montal, 2007b; 
Galloux et al., 2008; Lai et al., 2010). 
 
 The diameter of the HN pore has been estimated by electrophysiological methods 
and by measuring the escape of various differently sized fluorescent labelled molecules 
from inside lipid vesicles (Fu et al., 2002; Koriazova and Montal, 2003; Shone et al., 1987). 
The results of these investigations have determined the diameter of the pore to be 
between 1.5nm and 2.4nm. This variation in size may be evidence that the HN pore is a 
highly dynamic structure and alternates between open and closed conformational states.
  




 The purpose of the pore formed by the HN domain is to facilitate the translocation 
of the LC domain from the interior of a recycling synaptic vesicle into the cell cytosol 
(Montal, 2010). If the LC domain is replaced by an alternative (non-light chain) cargo 
protein, translocation does not occur suggesting that an ordered and specific set of 
interactions between the heavy chain and LC domain are required in order to facilitate LC 
movement (Goodnough et al., 2002).   
 
 The electrophysiological investigation of BoNT pore formation (see section 1.5.2.4) 
reported a series of blocked and unblocked pore states which have been interpreted as 
showing progression of the LC domain through the individual stages of translocation (Figure 
1-7). Firstly the pore appears blocked demonstrating a low conductance (approximately 13 
pS) followed by a series of intermediate stages thought to be the partial occlusion of the 
pore by the LC domain (24, 47 and 55pS), before finally the conductance stabilizes at a 
higher conductance (approximately 67pS) determined to be a unblocked pore state (Fischer 
and Montal, 2007b). Direct evidence that this electrophysiological method reports the 
translocation of the light chain domain, comes from observations that SNARE protein 
substrates added to the trans compartment are only proteolysed in experiments where all 




Figure 1-7 Sequence of events underlying BoNT LC translocation through the HC channel.  
Step 1, Crystal structure of BoNT/A holotoxin before insertion in the membrane. Then is 
shown a schematic representation of the membrane inserted BoNT/A during an entry event 
(step 2), a series of transfer steps (steps 3 and 4), and an exit event (step 5). (reproduced 
from (Fischer and Montal, 2007b)). 
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 An elegant series of studies identified that channel formation and LC domain 
translocation rely on three gradients between the cis and trans side of excised Neuro 2A 
cells: a pH gradient, a redox gradient and the transmembrane potential. If any of these 
gradients becomes disrupted LC translocation will not occur.  
 
 As has already been discussed, an acidic pH is required for LC domain unfolding and 
HN domain insertion into membranes; however, if a pH is not near neutral at the trans side 
of the membrane LC translocation will not occur. For example removal of the pH gradient 
prevented the heavy chain of BoNTB from forming conducting channels at acidic but 
symmetrical pH, upon neutralization of the trans compartment an acidic gradient was 
created restoring channel activity within 30 seconds (Hoch et al., 1985). 
 
 Similarly, a redox gradient is required (oxidizing cis and reducing trans) to facilitate 
LC domain translocation. The cis side of the membrane must be kept under reducing 
conditions otherwise the disulphide bond connecting the HN and LC domains will be 
reduced and only open pore formations will be observed. Concurrently, a reducing 
environment is needed at the trans side of the membrane to reduce the disulphide bond 
post translocation so that the LC domain may leave the pore formation assembly. 
(Koriazova and Montal, 2003). There is experimental evidence that the NADPH-thioredoxin 
reductase-thioredoxin system is responsible for reducing the BoNT disulphide bond in a 
cellular system (Pirazzini et al., 2013). 
 
 Once inside the cytoplasm the LC domain must refold in order to restore its 
enzymatic protease activity. This process is thought to prevent any reverse translocation 
which is shown in patch clamp assays as a permanent blocked pore (Koriazova and Montal, 
2003). It is not fully understood whether the refolding of the LC domain is spontaneous and 
unregulated but it has been hypothesized that the HN domain belt region may assist in this 
process (Fischer et al., 2008b). 
 




 Once the LC domain of BoNT has refolded in the physiological conditions of the cell 
cytoplasm it is free to locate SNARE protein substrates. SNARE proteins are core 
components of the vesicle membrane fusion apparatus and as such facilitate the 
interaction between vesicles containing molecules to be exocytosed and the cellular 
membrane. There disruption therefore is instrumental in preventing the release of 
acetylcholine into the synaptic cleft of motor neurones, resulting in flaccid muscular 
paralysis (Montal, 2010). 
 
  SNARE substrates are found at multiple locations; SNAP-25 and Syntaxin are 
attached to the plasma membrane and synaptobrevin (also called VAMP) is attached to 
vesicular membranes (Südhof and Rothman, 2009).  Each BoNT serotype has developed 
ways of accessing their respective substrate targets; for example, the localisation of the LC 
domain of serotypes A and E have been studied using fluorescent fusion proteins which 
show their localisation to the plasma membrane (LCA) and the cell cytoplasm (LCE) 
respectively (Fernandez-Salas et al., 2004). 
 
 The crystal structures of all seven serotypes of the BoNT LC domain have been 
solved providing evidence of a zinc protease domain which has similarities to thermolysin 
(Agarwal et al., 2005; Agarwal et al., 2009; Arndt et al., 2006; Arndt et al., 2005; Jin et al., 
2007; Segelke et al., 2004). The LC structure is constituted of a mixture of α-helicies and β-
strands and much like the HC domain displays a similar structure throughout all seven 
serotypes with an approximate sequence identity of 35%. Conserved residues which make 
up a tetrahedral co-ordination, characteristic of a HEXXH zinc binding motif, have been 
determined through mutation studies to be essential to the domains function (Binz et al., 
2002). Inactivation of BoNT’s SNARE catalysis through the select mutation of LC domain 
residues produces a non-toxic form of BoNT (also known as endonegative BoNT). 
 
 Each serotype of LC domain acts as a remarkably specific protease which shows 
specificity for a single peptide bond at a single SNARE proteins (with the exception of 
serotype C1 which is known to cleave both SNAP-25 and Syntaxin) (Binz, 2013). BoNT 
serotypes B, D, G and F proteolyse VAMP/Synaptobrevin-2 at separate peptide bonds 
identified in Figure 1-8; BoNT serotypes A, C and E proteolyses SNAP-25 at peptide bonds 
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identified in Figure 1-8; and BoNT serotype C has the capability to cleave two types of 
SNARE protein, namely, SNAP-25 and Syntaxin 1A (Binz, 2013). 
 
 It is known that exocytosis is a common process that occurs in most eukaryotic cell 
types. It is used for processes as diverse as membrane expansion during cell growth and the 
release of neurotransmitters from neurones (Darios and Davletov, 2006). This process, 
similar to cholinergic nerve terminal exocytosis, is regulated by SNARE proteins which form 




    
 
Figure 1-8 Schematic drawing of the substrate recognition sites for BoNT LC serotypes A-G 
The SNARE proteins known to be proteolysed by the Zn2+ dependent catalytic ability of 
BoNT are identified above. The position at which BoNT serotypes A-G cleave SNARE 





1.5.4 Composition of the synaptic vesicle 
 
As discussed, the endocytosis and translocation of BoNT relies on the toxins 
interaction with eukaryotic membranes. Consequently, to understand this interaction 
requires analysis of the composition of these membranes and specifically the endocytotic 
compartment (or synaptic vesicle, SV). 
 
In 2006, the purification and analysis of rat brain synaptic vesicles provided the first 
detailed picture of SV composition and physical characteristics by identifying and 
quantifying their proteinaceous and phospholipid components. Proteomic analysis 
identified 410 different proteins, of which, more than 80 were identified as integral 
membrane proteins. Quantitative western blot and dot blot analysis of a select few of these 
proteins identified a high proportion of previously known SV associated proteins, including, 
synaptophysin, synaptobrevin 2, syntaxin1, SNAP 25 and synaptotagmin 1 
(~10%,~8.6%,~2%,~0.4% and ~7% of total SV proteins respectively). The lipid composition 
of SVs was measured via electrospray ionization (ESI) coupled with collision-induced 
dissociation (CID) and mass spectrometry to contain a high cholesterol content, a low 
concentration of phosphatidylinositol and a high proportion of phosphatidylethanolamine 
(see Table 1-2) (Takamori et al., 2006).  
 
Quantitative analysis of the physical parameters of rat brain SVs determined the 
average proportions of protein, phospholipids and cholesterol per vesicle to be (17.1 ± 
0.19) x 10-18, 8.8 x 10-18 and 3.7 x 10-18 g/vesicle respectively, resulting in a total predicted 
dry mass of 29.6 x 10-18 g/vesicle. Further inspection of rat brain SVs using cryo-electron 
microscopy determined the average diameter of a vesicle to be ~40-45nm. Using this 
quantitative analysis of SV components and physical parameters, a molecular model was 
constructed using structurally defined membrane proteins. This model suggests a high 







Membrane Lipids ng lipid/µg protein 
  
Phosphatidylcholine         186 ± 37 
Phosphatidylethanolamine  
1- Ester         120 ± 18 
1- ester (plasmalogen)         96 ± 14 
Phosphatidylserine         68 ± 7.2 
Phosphatidylinositol 9.73 ± 10 
Sphingomyelin         37 ± 5.1 
Cholesterol          215 ± 25 
Hexylceramide 8.6 ± 4 
Ceramide  1.2 ± 0.1 
Protein : Phospholipid (w/w) 1.94 ± 0.23 
Table 1-2 Quantitative measurement of rat synaptic vesicle lipids via electrospray 
ionization coupled with collision-induced dissociation (CID) and mass spectrometry. 
(Takamori et al., 2006) 
 
Figure 1-9 Molecular model of an average rat Brain SV based  




1.5.5 Retargeting botulinum neurotoxin (targeted secretion inhibitors) 
  
 In 1985, trypsin was used to separate the receptor binding domain (HC) of BoNTA 
from the holotoxin molecule, thus leaving a seemingly stable protein composed of the light 
chain domain (LC) and translocation domain (HN) (Shone et al., 1985). This combination of 
the LC and HN domains was termed LHN. The LHN molecule was “activated” by cleaving a 
protease bond between the HN and LC domains using exoprotease to mimic host protease 
activation (Shone et al., 1985). LHN serotype A (LHA) was further determined to retain its 
catalytic activity and its ability to form pores under acidic conditions demonstrated though 
a vesicle leakage assay (Shone et al., 1987). However, removing the HC domain removed the 
inherent toxicity of the BoNT molecule by taking away its protein specific binding 
mechanism with cholinergic nerve terminals (Chaddock et al., 2002).  
 
 The recombinant production of LHN has since been further optimised leading to the 
expression and isolation of LHN serotypes A, B, C and D respectively. These constructs were 
codon optimised for recombinant expression in E.coli and included an affinity tag to aid in 
their purification (e.g. Maltose Binding Protein (MBP) or Histidine Tag). A specific activation 
site was added between the LC and HN domains to allow activation by specific proteases 
and thereby minimise non-specific enzyme digestion during production.  LHN molecules 
were found to be suitable for vaccine preparation and for tools to investigate SNARE-
mediated exocytosis (Fdez et al., 2008).  
 
 The three dimensional structures of LHA and LHB molecules have been defined 
through X-ray crystallography.  Through comparison of LHA and LHB molecules with the 
three-dimensional structures of BoNTA and BoNTB respectively, it has been determined that 
the removal of the HC domain does not significantly affect the structure of either the HN or 





Figure 1-10 The crystallographic structures of LHA and LHB proteins  
The crystallographic structures of LHA and LHB demonstrate that the HN and LC domains of 
BoNTA and BoNTB are stable in the absence of the HC domain. (Masuyer et al., 2011; 
Masuyer et al., 2009) 
  
 Following removal of BoNTs specificity for the cholinergic nerve terminal, the 
concept of targeting the catalytic action of BoNT molecules to various cell types was 
investigated. The principle of retargeting BoNT derivatives has been demonstrated in four 
studies in which LHN serotypes A, C and D have been successfully targeted towards both 
neuronal and non-neuronal cell types.    
 
 When LHA was chemically conjugated to nerve growth factor (NGF) or wheat germ 
agglutinin (WGA), it was shown to inhibit the release of noradrenaline in neuronal cells and 
insulin secretion in a pancreatic cell lines respectively, through the cleavage of intracellular 
SNAP-25 protein. This demonstrates the ability of LHN molecules to bind with, translocate 
into and have catalytic effect in both neuronal and non-neuronal cell lines (Chaddock et al., 
2000b). 
 
 The first in-vivo demonstration of targeted LHN action was seen following its 
chemical conjugation with a lectin from Erythrina cristagalli (ECL) which was shown to 
specifically bind to nociceptive afferent neurones (Duggan et al., 2002). This molecule was 
shown to have the ability to successfully inhibit the release of substance P in several models 




 To target the action of LHN toward non-neuronal cell lines, LHC was expressed in 
conjugation with epidermal growth factor (EGF). This molecule was proven to inhibit the in-
vitro release of mucin in human pulmonary epithelial cells, thus showing a therapeutic 
potential in the treatment of chronic obstructive pulmonary disease (Foster et al., 2006). 
 
 Most recently, the recombinant expression of LHD with a growth hormone receptor 
hormone (GHRH) binding domain specifically inhibited the release of pituitary somatotroph 
growth hormone (GH) release though the intercellular cleavage of vesicle associated 
membrane proteins (VAMP) in-vitro and in-vivo. This presents further evidence of the 
potential of targeted secretion inhibitors (TSI) for targeting diseases caused by the hyper-





1.5.6 Aims of the project 
 
 Botulinum neurotoxins inhibit neurotransmission at cholinergic nerve terminals 
through entering a neuromuscular junction and cleaving SNARE proteins (which are critical 
for exocytosis).  Much is known regarding the specificity with which BoNT targets motor 
neurones and the mechanism by which they cleave SNARE proteins, however, only limited 
and sometimes conflicting information is available regarding how BoNT interact with 
cellular membranes. Here we investigate the interactions between recombinant, 
endopeptidase inactive BoNT proteins and catalytically active LHN proteins, with cellular 
and artificial membranes to provide insight into the way in which BoNTs and their 
derivatives interact with membranes. 
 Firstly, an interaction between LHN serotype D and CHO-K1 cells was investigated to 
detect whether LHD proteins interact with membrane bound G-protein coupled receptors 
(GPCRs). This was completed both to assure that LHD did not serendipitously interact with 
G-protein coupled receptors (GPCR’s) and to further assess whether LHD interacts with 
cellular membranes at physiological pH (section 3.1). 
 Secondly, to further investigate the serotype specific differences inherent in BoNT 
structure, LHD was recombinantly expressed, purified and crystallised in an attempt to 
elucidate its novel three-dimensional structure via X-ray crystallography. Furthermore, 
novel purification procedures were developed to isolate the HN domain of BoNT serotypes 
A, C and D so to further understand their physical properties (section 3.2). 
 Finally, to further investigate the method by which BoNT and LHN proteins interact 
with phospholipid membranes, a 96 well vesicle leakage assay was designed and developed 
to quickly and efficiently provide evidence of the pore forming potential of BoNT and LHN 
molecules. This was performed to uncover for the first time, differences in the pore forming 
potential of various BoNT and LHN serotypes (section 3.3, 3.4 and 3.5). 
  
 





2.1 Chemicals and reagents 
 
 All chemicals and reagents were purchased from Sigma-Aldrich unless otherwise 
stated. 
 
2.2 DNA processing 
 
2.2.1 Agarose gel electrophoresis 
 
 1% agarose gels were prepared by dissolving 1g agarose powder (Quiagen) in 
100ml’s of TAE buffer (40mM Tris Acetate, 1mM EDTA, pH8) whilst heating. The agarose 
solution was poured onto a gel mould and left to cool and set. 50µl DNA samples were 
prepared with SYBR safe stain (Invitrogen) prior to loading into the agarose gel (15µl’s per 
well). NEB DNA ladders were used as molecular weight markers (1kbp or 100bp). 
Electrophoresis was carried out in TAE buffer using a Bio-Rad gel tank at 150 Volts. The DNA 
bands were analysed under UV light (InGenious, Syngene). 
 
2.2.2 DNA plasmid isolation 
 
 Microbank beads coated with Top 10 cells pre-transformed with recombinant DNA 
by Syntaxin Ltd, were placed in 10ml modified Terrific Broth (mTB, #T0918) with an 
appropriate antibiotic and grown overnight at 37°C in a shaking incubator (200rpm). The 
cells were harvested via centrifugation and the DNA isolated using a Wizard® plus SV 
miniprep system (Promega) as per the manufacturer’s instructions. 
  
2.2.3 Restriction endonuclease digestion 
 
 Specific recognition sites were identified in the DNA sequence using SeqBuilder® 
(DNASTAR), the restriction sites were then cleaved using restriction enzymes from NEB with 




 Digestions were either completed as sequential digestions or double digestions; 
sequential digestions were completed using two individual (single) digestions separated by 
a DNA purification step (Wizard® plus SV DNA purification system (Promega) using the 
manufacturers protocol); double digestions were completed using one digestion step (two 
restriction sites cleaved) again following the manufacturers protocols. All digestions were 
completed over 3hrs at 37°C. The subsequent DNA fragments were purified using 1% 
agarose gel electrophoresis (section 2.2.1). 
 
2.2.4 DNA ligation 
 
 DNA ligation was completed in a microcentrifuge tube placed on ice. A mixture of 
2µl 10x T4 DNA Ligase Buffer, 50ng Vector DNA, 50ng Insert DNA and 1µl DNA ligase was 
pippetted into the microcentrifuge tube before making up the solution volume to 20µl 
using Nuclease-free water. The reaction was briefly mixed by gently pipetting up and down 
within the microcentrifuge tube. The reaction was then incubated at room temperature for 





 A 50µl vial of TOP 10 cells (NEB) was thawed from -80°C on ice before the addition 
of 5µl’s ligations mixture (section 2.2.4), it was then gently mixed by flicking the vials base. 
Following mixing, the vial and its contents were incubated on ice for 20 minutes prior to 
placing in a water bath heated to 42°C for 45 seconds (heat shock) before it was transferred 
back to ice for 10 minutes (care was taken not to agitate the mixture so to not shear DNA 
being taken up by cells). 150µl of modified Terrific Broth (mTB, #T0918) was then added to 
the mixture before incubating at 37°C for 60 minutes in a shaking incubator (225rpm). The 
mixture was then plated out onto pre-prepared agar plates inoculated with 1ng/ml 
Kanamycin and left to dry for 30 minutes. Finally, the agar plates were placed in a 37°C 






 After transformation of ligations in TOP10 competent cells, three individual 
colonies were selected from the agar plate and transferred into three 50ml falcon tubes 
containing 10ml modified Terrific Broth (mTB) growth media. DNA plasmid isolation 
(section 2.2.2) was then used to produce sufficient quantities of plasmid DNA for 
sequencing. 
 
 Samples were sent for sequencing to Source BioScience (Oxford, UK). The results 
generated were examined using the SeqMan software (StarLabs). 
 
2.3 Protein methods 
 
2.3.1 SDS-PAGE and western blot analysis  
 
 Protein samples were mixed with LDS sample buffer (x4) (Life Technologies) and 
heated to 90°C for five minutes before centrifuging for 1 minute on a bench top centrifuge. 
NuPAGE 4-12 % bis-tris gels were loaded with samples and ran at 200 Volts for 55 minutes. 
Gels to be stained were washed with dH2O and stained with warm Coomassive SafeStain for 
30 minutes before de-staining by washing several times with dH2O and finally leaving in 
dH2O for up to an hour. Gels to be blotted were assembled in the transfer assembly and 
blotted at 0.4mA for 1 hour onto nitrocellulose membrane in methanol free blotting buffer 
(Pierce cat no.350400). 
 
 Nitrocellulose blots were blocked for 1 hour with 0.5% BSA in PBS-0.1% Tween 20 
(PBS-T) before they were probed with in-house rabbit polyclonal antibody (5 μg/ml, 1:1000 
dilution) in 0.5 % BSA/ PBS-T for 1 hour. The blots were washed with 3 changes of PBS-T 
over 15 minutes before incubating with secondary antibody at 1:1000 dilution in PBS-T for 1 
hour. The blots were washed again and developed with SuperSignal DuraWest substrate as 
per the manufacturer’s instructions. All incubations and washes were carried out at room 
temperature with gentle rocking. The developed blots were imaged using a Syngene 




 Gels used for SDS-PAGE analysis were loaded with 5μl of Benchmark ladder (NEB) in 
the left-hand lane and 10μl of protein sample/LDS sample buffer in subsequent wells. Gels 
used for western blott analysis were loaded with 3μl of Magicmark (NEB) in the left-hand 
lane and 15μl of protein sample/LDS sample buffer in subsequent wells. 
 
2.3.2 Protein expression 
 
 100 ml of modified Terrific Broth (mTB) in a 250 ml plastic flask was supplemented 
with  0.2% glucosamine and 30μg/ml kanamycin before inoculating with one microbank 
bead coated with BL21 DE3 cells (from Syntaxin Ltd expression microbanks) and incubated 
at 37 °C, 225 rpm.  
 
 The next day, 10 ml of the overnight culture was used to inoculate 1L of modified 
TB containing 0.2% glucosamine, 30μg/ml Kanamycin and 20mL of 50mM Hepes, 500mM 
NaCl, pH7.2. An OD600 value of the overnight culture was determined by making 1:10 or 
1:20 dilution in the appropriate media. After inoculation, the flasks were returned to the 
incubator and incubated at 37°C, until an OD600 of 0.5-0.6 was reached, at which point the 
incubator temperature was dropped to 16°C for 1 hour before inducing the cultures with 
1mM IPTG. Again, the OD600nm value was determined by making 1:2 or 1:10 dilution in 
the appropriate media. The expression cultures were then incubated overnight for 
approximately 20 hours.  
 
 Prior to harvest OD600 values for each culture were determined by making a 1:20 
dilution with the appropriate media. Cultures were then transferred to 1L pots and 
harvested by centrifugation at 5000rpm for 20 minutes (4°C). The supernatant was 
decanted and the cell pellets were resuspended in 20ml’s of lysis buffer (see section 3.2.2). 
The cell pastes were then weighed and the wet cell weight was calculated before storing 
the cell pastes in 50mL centrifuge tubes at -80°C. 
 




 The expression cell paste was removed from the -80°C freezer and thawed by 
incubating the tubes in a beaker of cold water before being re-suspended in 60-70ml of 
lysis buffer. After re-suspension the sample was incubated for 1 hour under stirring in a 
cold room (2-8°C). When the cell paste was completely re-suspended, cells were 
homogenized at 20kPsi with a single pass through a Constant Systems homogenizer, 
previously washed using 0.1M NaOH then dH2O before equilibriating with the determined 
lysis buffer. After homogenization the cell debris was removed by centrifugation. The 
samples were spun at 13,500 rpm for 60 minutes at 4°. Supernatant finally filtered using a 














3.1.1.1 LHN proteins inhibit cellular secretion 
 
 The intoxication of Botulinum neurotoxin (BoNT) (serotypes A-H) is thought to 
occur in three distinct phases: a receptor binding phase, an internalization phase and a 
catalytic phase, ultimately causing the inhibition of presynaptic neurotransmitter release. 
The structure of all BoNT serotypes is thought to conform to a tri-modular architecture 
which facilitates these three stages using three domains: the receptor binding domain (HC), 
translocation domain (HN) and catalytic domain (LC) (Turton et al., 2002). Removing the HC 
domain of BoNTs, either by proteolytic cleavage or cloning and expression, produces LHN 
molecules (Chaddock et al., 2004). LHN molecules possess the translocation and catalytic 
ability of BoNT molecules without possessing their potential to specifically bind to the pre-
synaptic terminal of motor neurons (Chaddock et al., 2004). By adding a new specifically 
designed targeting domain to the LHN protein it is possible to target their effect to non-
neuronal and neuronal cells of potential therapeutic interest (Chaddock et al., 2004; 
Chaddock et al., 2000a; Chaddock et al., 2000b; Leggett et al., 2013).  
 
 The targeting and effect of LHN molecules has been demonstrated in four studies. In 
the first study, Nerve Growth Factor targeted LHA (NGF-LHA) was targeted to nerve growth 
factor receptors causing SNAP-25 cleavage and consequently inhibiting the release of 
noradrenalin from neuronal cells (Chaddock et al., 2000a). In the second study, Wheat 
Germ Agglutinin lectin receptor targeted LHA (WGA-LHA) was targeted to wheat germ 
agglutinin lectin receptors inhibiting neurotransmission from several neuronal cell types 
and insulin secretion from a pancreatic cell line (Chaddock et al., 2000b). In the third study, 
LHA was chemically conjugated with a lectin from Erythrina cristagalli to target primary 
nociceptive afferents and inhibit the release of neurotransmitters, glutamate and substance 
P with a duration of action similar to that of its holotoxin equivalent. This study confirmed 
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the efficacy of targeted LHN proteins in-vivo. (Chaddock et al., 2004). Finally, LHD 
recombinantly expressed with a Growth Hormone Receptor Hormone (GHRH) binding 
domain successfully inhibited the release of pituitary somatotroph growth hormone (GH) 
in-vitro and in-vivo (Leggett et al., 2013). 
 
3.1.1.2 Bradykinin B1 receptor targeting 
 
 Kinins are a group of biologically active peptides that exert a number of 
physiological effects, including vasodilatation, smooth muscle contraction, inflammation 
and pain induction.  The physiological effects of Kinin molecules are mediated through the 
stimulation of bradykinin B1 and B2 G-protein coupled receptors. B1 receptors have been 
shown to have a low level of expression which is up-regulated in the presence of cytokines 
and endotoxins or during tissue injury. The B1 receptor participates in chronic inflammation 
and pain and has been identified as a potential drug target for the treatment of those 
conditions (Wu et al., 2012). In vivo studies indicate that B1 receptor antagonists can 
reverse streptozotocin-induced chronic pain in rate models of diabetes (Dias et al., 2007).   
 
 Agonist stimulation of the bradykinin B1 receptor results in the receptor mediated 
stimulation of phospholipase C and hydrolysis of phosphatidylinositol bisphosphate, leading 
to the formation of the two second messengers, namely, Ins(1,4,5)P3 and diacylglycerol. 
Ins(1,4,5)P3 interacts with a receptor on the endoplasmic/sarcoplasmic reticulum that 
functions as a Ca2+ release channel which serves to increase cytosolic free Ca2+ ultimately 
stimulating inflammatory responses (Mathis et al., 1996).  
 
 Des-Arg9-BK is a kinin metabolite which selectively activates Bradykinin B1 
receptors. By assessing Des-Arg9-BK potency it is possible to determine stability in the 
recombinant expression of the Bradykinin B1 receptor and lack of Bradykinin B2 receptor 




3.1.1.3 Investigation of LHD effects on Bradykinin B1 receptors 
 
 Experiments were conducted by Syntaxin Ltd aimed at targeting LHN towards the 
Bradykinin B1 receptor so to prospectively inhibit cellular secretion at sites of inflammation 
and pain. To confirm that a targeting domain is necessary for LHN proteins to bind to the 
Bradykinin B1 receptor, LHN molecules (serotypes A-D) with no targeting domain were 
assessed for their ability to stimulate intracellular Ca2+ release in cells engineered to stably 
express the Bradykinin B1 receptor. Experiments completed by Syntaxin Ltd demonstrated 
that LHD stimulated an unexpected increase in intracellular Ca
2+ ion concentration in CHO-
K1 cells which expressed the recombinant Bradykinin B1 receptor. 
 
 Here we investigate the interaction of LHN serotype D (LHD) with recombinant 
Bradykinin B1 receptors expressed on CHO-K1 cells. Through comparison of the interaction 
of LHD with CHO-K1 cells which do and do not express the Bradykinin B1 receptor 
respectively, we were able to determine that LHD induced increases in intracellular Ca
2+ 







3.1.2.1 Culture of CHO-K1-B1 cells 
 
 CHO-K1 cells with stable recombinant expression of the human Bradykinin B1 
receptor (CHO-K1-B1 cells) were cultured in media (Ham’s F12, 2mM glutamine, 10% FBS 
and 400µg/ml G418) at 37°C, 5% CO2. Cells were passaged when they reached 80% 
confluency (every 3 to 5 days). The media was removed and the cells washed twice with 
PBS. Cells were harvested in PBS-based non-enzymatic cell dissociation buffer (37°C) for 2 
minutes, pelleted by centrifugation (1,500rpm; 3 minutes), re-suspended in cell culture 
media and seeded into fresh T500 flasks. 
 
3.1.2.2 Ca2+ mobilisation assay 
 
 The intracellular increase of cytosolic free Ca2+ was measured in-vitro using Ca2+ 
sensitive dye (FLIPR® Calcium Assay Kit) (Simpson et al., 2000). CHO-K1-B1 cells (20,000 
cells.well-1) were seeded into 96 well black walled/clear bottomed half area plates (costar) 
16 hours prior to performing the assay. On the day of the assay, plates were incubated 
(37oC; 5% CO2) in HBSS modified assay buffer containing 0.5X Ca
2+ sensitive dye and 
probenecid (2.5 mM). After 1 h, increasing concentrations of des-Arg9-BK (3pM-3μM) or LHD 
(10pM- 1μM, provided by Syntaxin Ltd) were added to the cells in triplicate rows by the 
FlexStation3® (height 70μl; speed 16μl.s-1; 37oC). Fluorescence was measured at 525nm 
measured over 60 seconds and recorded as RFU signal. Ca2+ mobilisation was quantified as 
% increase in baseline RFU (Equation 1).  
 
3.1.2.3 Data handling and statistical analysis 
 




 Raw Ca2+ fluorescence traces were converted into single numerical values of 
maximum minus minimum (RFU units) using Softmax Pro software. The minimum RFU point 
was subtracted from the peak RFU point during the 60 second total read time. 
 
 Data points were plotted on the y-axis as percentage increase in baseline RFU 
measurements using Equation 1. Baseline RFU was estimated from the first 20 seconds of 
reading (before addition of agonist or LHD), this normalised the response measured in each 
well of the plate using the baseline value, thus correcting for any slight variation in cell 
density between wells.  
 
% Increase Baseline = (peak RFU – baseline RFU) x 100  (Equation 1) 
   Baseline RFU 
 
 Potency of agonist was estimated by fitting RFU data (% increase in baseline) and 
logarithmic agonist concentration into a four parameter logistic equation (a modified Hill 
equation; Equation 2). The four parameters of this equation include minimum response 
(basal), maximum response (max or Emax), the concentration required to produce a 
response half way between the minimum and maximum response (EC50) and the slope 
factor (Hill slope (nH)). 
 
y = basal + (max-basal)      (Equation 2) 









3.1.3.1 LHD induces an increase in CHO-K1 intracellular calcium 
 
 Des-Arg9-Bradykinin (des-Arg9-BK) binds to and activates the Bradykinin B1 
receptor, this activation can be monitored through measuring an increase in intracellular 
Ca2+ using Ca2+ sensitive dye (Simpson et al., 2000). Consequently, by measuring the 
intracellular Ca2+ levels of cells, following their incubation with des-Arg9-BK, it is possible to 
determine the presence or absence of the Bradykinin B1 receptor. 
 
 The increase in intracellular Ca2+ levels caused by the incubation of CHO-K1-B1 cells 
with des-Arg9-BK (0.3pM to 0.3µM) demonstrated the presence and stable recombinant 
expression of the Bradykinin B1 receptor on CHO-K1-B1 cells (Figure 3-1, A). Specifically, 
des-Arg9-BK induces a concentration dependent increase of intracellular Ca2+ in CHO-K1-B1 
cells, demonstrating a pEC50 of 10.21 ± 0.10 standard error mean (s.e mean).  A similar 
incubation of des-Arg9-BK (0.3pM to 0.3µM) with wild type CHO-K1 cells (not transfected 
with the receptor) did not trigger an increase in intracellular Ca2+ demonstrating that the 
Bradykinin B1 receptor is not expressed on CHO-K1 cells.  
 
 It was found that incubating concentrations of 1, 0.33 and 0.1µM LHD with CHO-K1-
B1 cells caused a small but measurable increase in intracellular Ca2+ levels (Figure 3-1, B). In 
an effort to determine whether the increase in intracellular Ca2+ was due to LHD activation 
of the Bradykinin B1 receptor, the same experiment was repeated using CHO-K1 cells; the 
incubation of CHO-K1 cells with 1, 0.33 and 0.1µM LHD caused a similar increase in 
intracellular Ca2+ levels (Figure 3-1, D).  Specifically, 1, 0.33 and 0.1µM LHD caused increases 






Figure 3-1 LHD causes an increase in intracellular calcium levels in CHO-K1-B1 and CHO-K1 
cells.  
Through measuring intracellular Ca2+ levels the effect of des-Arg9-BK and LHD on CHO-K1-B1 
and CHO-K1 cells is shown (A) Effect of des-Arg9-Bradykinin (0.3µM- 0.3pM) on CHO-K1-B1 
cells (pEC50 = 10.10 ± 0.06 s.e mean, nH = 1.41 ± 0.24 s.e mean) (B) Effect of LHD (1µM- 
10pM) on CHO-K1-B1 cells (n=3). (C) Effect of des-Arg9-Bradykinin (0.3µM- 0.3pM) on CHO-
K1 cells (D) Effect of LHD (1µM- 0.01µM) on CHO-K1 cells (n=3). 
 
3.1.3.2 Reducing extra-cellular Ca2+ levels inhibits LHD induced intra-cellular Ca
2+ increase 
 
  Repeating experiments to determine the LHD induced increase of intracellular Ca
2+ 
at CHO-K1 and CHO-K1-B1 cells respectively (Figure 3-2, A) identified a similarity between 
the two responses. Specially, an LHD concentration of 1µM induced a mean increase in 
intracellular Ca2+ of 64.4% and 63.7% in CHO-K1-B1 and CHO-K1 cells respectively.  
 
 In order to investigate whether extracellular Ca2+ concentration affects the increase 
in intracellular Ca2+ concentration caused by 1, 0.33 and 0.1µM LHD, the experiment was 
repeated using two different formulations of extracellular buffer (with and without Ca2+). 
 42 
 
Removing extracellular Ca2+ decreased the potential of LHD to increase intracellular Ca
2+ 
levels in CHO-K1 cells, suggesting that LHD facilitates an influx of extracellular Ca
2+ to the 
intracellular compartment (Figure 3-2, B). When the concentration of extracellular CaCl2 
was decreased by 1.26mM, the intracellular Ca2+ fluorescence decreased from 37.5% to 
12.2% (1µM LHD). 
 
 Variability of LHD induced increase in intracellular Ca
2+ concentration for both CHO-
K1 and CHO-K1-B1 cells respectively was evident throughout this study. Further 
investigation into LHD induced increase in intracellular Ca
2+ resulted in an inability to 
reproduce the response. For this reason the previous results identifying LHD induced 
increase in intracellular Ca2+ could not be qualified as significant and the investigation was 
terminated.  
 
Figure 3-2 Reducing the concentration of extracellular Ca2+ inhibits LHD induced increases 
in intracellular calcium.  
Through measuring intracellular Ca2+ levels, the effect of LHD on CHO-K1-B1 and CHO-K1 
cells is determined with and without extracellular Ca2+  (A) A comparison of the effect of 
LHD (1µM- 10pM) on CHO-K1-B1 and CHO-K1 cells (n=3). (B) The effect of removing 








 Removing the HC domain of BoNT proteins, removes their specificity for the pre-
synaptic terminal of neuromuscular synapses and consequently their natural toxicity. BoNT 
proteins without HC domains are termed LHN proteins; by fusing a ligand with affinity for 
specific cell surface protein receptors of a target cell, the SNARE cleavage potential of LHN 
proteins has been targeted to specific cell types. (Chaddock et al., 2004; Chaddock et al., 
2000a; Chaddock et al., 2000b). The activity of targeted LHN molecules has lead to the 
development of a range of targeted secretion inhibitors (TSI’s) by Syntaxin Ltd with an 
objective to develop therapeutic molecules. To qualify that LHN proteins are targeted 
towards specific cell types, they should not bind serendipitously to cellular receptors. Any 
random binding of LHN molecules to cellular receptors may suggest inherent toxicity in the 
molecule and cast doubts on to the molecules potential as a therapeutic.  
 
 Here we investigate LHD induced increase in intracellular Ca
2+ in CHO-K1 cells in an 
attempt to further understand how LHD interacts with eukaryotic cells.  
  
3.1.4.1 Bradykinin B1 receptors are stably transfected onto CHO-K1 cells 
 
 The Bradykinin B1 receptor was confirmed to be stably expressed on CHO-K1-B1 
cells through detecting Bradykinin B1 receptor activation via a des-Arg9-BK induced increase 
in intracellular Ca2+ (Mathis et al., 1996; Simpson et al., 2000). Similarly, the absence of the 
Bradykinin B1 receptor on CHO-K1 cells was determined through a lack of response to the 
des-Arg9-BK agonist (Figure 3-1, C). By determining the presence and absence of the 
Bradykinin B1 receptor on CHO-K1-B1 and CHO-K1 cells respectively, whether or not a 
cellular response is directly attributable to Bradykinin B1 receptor activation can be 
assessed. 
 




3.1.4.2 LHD facilitates an increase in CHO-K1 and CHO-K1-B1 cell intracellular Ca
2+ levels 
 
 CHO-K1 and CHO-K1-B1 cells demonstrate an increase in intracellular Ca2+ 
concentration in the presence of LHD (Figure 3-1, B and D). This implies that LHD either 
stimulates an increase in intracellular Ca2+ from an intracellular source, activates an 
endogenous receptor or Ca2+ channel on the cell surface, or uses its ability as a pore 
forming protein (Fischer and Montal, 2007b) to form ion channels in the cellular membrane 
through which extracellular Ca2+ may permeate.  
 
 Through determining that LHD has a similar effect at both CHO-K1 and CHO-K1-B1 
cells (Figure 3-1, A and Table 3-1), we can conclude that LHD proteins are not causing an 
increase in intracellular Ca2+ by activating the Bradykinin B1 receptor.  
 
 
Cell Type Molecules pEC50 nH Emax 
CHO-K1-B1 Des-Arg9-BK 10.01 ± 0.06 1.41 ± 0.24 257.5 ± 11.33 
CHO-K1 Des-Arg9-BK n/a n/a n/a 
CHO-K1-B1 LHD n/a n/a 46.58 
CHO-K1 LHD n/a n/a 66.34 
Table 3-1 Measured increase in CHO-K1 and CHO-K1-B1 cell intracellular Ca2+ following 
addition of Des-Arg9-BK or LHD  
Through measuring intracellular Ca2+ levels, the effects of des-Arg9-BK and LHD on CHO-K1-
B1 and CHO-K1 cells are shown. pEC50, nH and Emax data presented for the agonist 
response of des-Arg9-BK at CHO-K1-B1 cells is from curve fitting within GraphPad Prism; n = 
3 experiments in all cases (pEC50, nH and Emax values are shown within 95% confidence 
limits). Emax values presented for the effect of LHD upon CHO-K1 and CHO-K1-B1 cells 
represent the mean maximum response measured for the respective interaction (n = 3). 
 
 Decreasing the concentration of extracellular Ca2+ effectively reduced the increase 
in intracellular Ca2+ levels induced by the interaction of LHD with CHO-K1 cells (Figure 3-2, 
B). There are many possible explanations for this, which include: (1) the binding of LHD to an 
unknown endogenous receptor is Ca2+ dependent, when bound this elicits a G-protein 
response and release of intracellular calcium stores; (2) LHD induces an influx of 
extracellular Ca2+ through a mechanism ultimately causing the flow of Ca2+ ions through 
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Ca2+ channels; (3) LHD interacts with CHO-K1 cells forming a pore through which 
extracellular Ca2+ enters the cell, causing an increase in intracellular Ca2+ levels (LHNs are 
pore forming proteins capable of forming pores through which conductance has been 
measured (Fischer et al., 2008b)).  
 
 If LHD is capable of forming a pore in the membrane of CHO-K1 cells under near 
physiological conditions this would suggest that LHD does not conform to the low pH 
induced pore forming model currently accepted for BoNT proteins. Concurrently, the 
endogenous expression of GPCR’s in CHO-K1 cells is well established (Holdsworth et al., 
2005); if LHD is effecting the release of intracellular Ca
2+ through activating an endogenous 
GPCR, it should be possible to determine a dose response effect through increasing the 
concentration of LHD beyond 1µM. 
 
 Ultimately, the effect elicited by LHD in CHO-K1 cells could not be isolated due to a 
lack of reproducibility. To determine whether LHD does permeate cellular membranes 
further analysis would be required; analysis of LHD membrane interaction through either 
vesicle leakage or patch clamp analysis may provide evidence of the proteins potential to 
permeate membranes at a physiological pH (Fischer et al., 2009; Lai et al., 2010). 
   
3.1.5 Conclusion  
 
 LHD has been assessed for its potential to cause an increase in CHO-K1 cell 
intracellular calcium in the absence and presence of the Bradykinin B1 receptor. These 
results suggest that the Bradykinin B1 receptor has no bearing on any effect of LHD on Ca
2+ 
influx into CHO-K1 cells. 
 
 The apparent LHD induced increase in intracellular Ca
2+ was small and poorly 
reproducible. Initially we were concerned that it might represent an off-target effect of LHD 
that could be problematic for development of therapeutic proteins incorporating that 
backbone. However the evidence presented in this chapter does not support that. If LHD 
does have the potential to stimulate Ca2+ signalling or form pores in cellular membranes 
directly, then further analysis, through an assay known to have the capability to measure 
 46 
 
pore formation (e.g. vesicle leakage or patch clamp assays) would be required to 
investigate it. Based on these results there is no strong evidence to suggest LHD is 








 Following the discovery that Botulinum toxins (BoNTs) are the causative agents of 
Botulism, efforts have been made to isolate BoNTs from bacteria using recombinant 
technology to express the desired protein and purification techniques to extract it. 
Subsequent development of these techniques has not only facilitated the elucidation of the 
crystallographic structure of BoNT serotypes A, B and E, but has also allowed the 
investigation of BoNTs mechanism of action (MoA) and the industrial production of BoNT 
serotypes A and B as pharmaceutical products (Kumaran et al., 2009; Lacy et al., 1998; 
Swaminathan and Eswaramoorthy, 2000). 
 
3.2.1.1 Purification of singular botulinum toxin domains 
 
 Following the elucidation of BoNTA’s crystallographic structure, it was clear that it 
contained three separate domains, namely, the receptor binding domain (HC), the 
translocation domain (HN) and the catalytic domain or light chain (LC) (Figure 3-3) (Lacy et 
al., 1998); the tri-modular architecture of BoNT has subsequently also been seen in the 
crystallographic structures of BoNT serotypes B and E respectively (Kumaran et al., 2009; 
Swaminathan and Eswaramoorthy, 2000). Given that separate functions have been 
proposed for each BoNT domain, there is great intrinsic value in the expression and 
purification of isolated BoNT domains so that their physical properties and function may be 





Figure 3-3 The three domains of Botulinum toxins 
The receptor binding domain (HC), translocation domain (HN) and catalytic domain or light 
chain (LC) of Botulinum neurotoxin serotype B (Swaminathan and Eswaramoorthy, 2000). 
 
 Seven serotypes (A-G) of the HC and LC domains of BoNT have been expressed, 
purified and crystallised in isolation. In contrast, the HN domain for only one serotype has 
been expressed and purified in isolation (serotype A). Previous expression and purification 
of HN domain (serotype A) has identified a hydrophobic protein which requires detergent to 
remain soluble before and during purification (Lai et al., 2010). When purified, the HN 
domain has provided information as to how BoNTA may form pores in vesicle and cellular 
membranes (Fischer et al., 2012; Lai et al., 2010).  
 
 The crystallographic structures of BoNT serotypes A, B and E have revealed the 
three dimensional structure of the HN domain; however, the crystallographic structures of 
HN domain serotypes C, D, F, G and H are without structural solution. Through the 
expression, purification and crystallisation of the remaining HN domain proteins, it may be 
possible to gain further insight into the least understood mechanism of BoNT action, 
namely, the way in which it forms a pore in synaptic vesicles at acidic pH (see Introduction 
1.5.2.4).  
 
3.2.1.2 Purification and crystallization of LHN proteins 
 
 The expression and purification of recombinant LHN proteins (serotypes A and B) 
has been completed to discover their functional properties and crystallographic structure 
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(Masuyer et al., 2011; Masuyer et al., 2009). This has demonstrated that LHN proteins can 
be purified, are stable when crystallized and their domains show little structural variation in 
comparison to full length BoNT molecules. (Chaddock et al., 2004). Given the successful 
expression and purification of recombinant LHN molecules and their inherent lack of 
toxicity, LHN proteins may be a promising and convenient way of solving unknown HN 




 Analysis of protein purification has for years provided a much needed insight into 
the physical properties of isolated proteins in solution. In this chapter we explore the 
purification of protein domains derived from various BoNT serotypes to assess their 
physical properties and to use these proteins in further studies (e.g. crystallisation trials and 
vesicle leakage assays).  
 The following molecules have been expressed and purified.  (1) LHN serotype D 
(LHD); LHD has been expressed, purified and crystallised in an attempt to elucidate its three-
dimensional structure via X-ray crystallography. (2) HN domain serotype D; The LC and HN 
domains of LHD have been separated in order to further understand the interaction 
between these two domains and to isolate the HN domain for further studies. (3) HN domain 
serotype A; the HN domain of BoNT serotype A has been cloned, expressed and purified to 
further understand its physical properties and for use in further experiments. (4) HN 
domain serotype C; this is the first recorded cloning, expression and purification of the HN 
domain of BoNT serotype C, this was completed to understand its physical properties and 






3.2.2 Materials and methods 
 
3.2.2.1 C and N-terminal His-tagged LHD cloning and expression 
 
 Synthetic genes were designed encoding LHD with a C or N terminal 10x Histidine 
tag (His-tag); and with either Enterokinase (DDDK) or Factor Xa (IEGR) cleavage sites 
(separating the LC and HN domains). These were cloned into a modified pMAL-c2x vector 
(NEB, UK) and transformed into E. coli BL21 cells by Syntaxin Ltd. Expression of these LHD 
constructs was carried out by inoculating a 100ml volume of terrific broth complex medium 
containing 100µg/ml Kanamycin (mTB) with expression cells. Following a 12 hour 
incubation at 37°C (shaken at 200rpm), 10ml of cell culture was transferred to a 1L volume 
of  mTB in a 2L conical flask subsequently shaken at 200 rpm (37°C) until the OD600 reached 
a value of 0.6. The temperature was then lowered to 16°C for induction with 1mM IPTG and 
left to grow overnight. The cells were then harvested, re-suspended in a minimal volume of 
25mM Tris, 500mM NaCl pH8 (suspension buffer) and stored at -80°C until further use. 
 
3.2.2.2 C and N-terminal His-tagged LHD purification  
 
Cell paste was thawed at a ratio of 1g cell paste: 100ml suspension buffer before 
lysis using a homogeniser (Constant Systems Ltd). The lysate was centrifuged at 20,000 g for 
one hour. The supernatant was filtered and loaded onto a 20ml Ni2+ charged chelating 
sepharose column (GE Healthcare). Fractions were eluted at imidazole concentrations of 
30, 100, and 250mM imidazole respectively (25mM Tris, pH8, 200mM NaCl) (Figure 3-4, 
(A)). The fractions of interest (determined by SDS page) were pooled together and dialysed 
overnight at 4°C against 25mM Tris, pH8, 200mM NaCl. Enterokinase and Factor Xa (New 
England Biolabs) treatment was carried out to mimic the native protein endoprotease 
activation by C. botulinum for N terminal and C-terminal his-tagged LHD, allowing formation 
of a two-chain (LC and HN) protein. Enterokinase digestion was completed by adding 1 unit 
of Enterokinase per 0.1mg LHD followed by incubation at room temperature for four hours. 
Factor Xa digestion was completed by adding 1 unit of Factor Xa per 0.1mg LHD at 25⁰C for 
12 hours. Ammonium sulphate solution was added to the cleaved fusion protein to reach a 
loading concentration of 1M before loading onto a 20ml phenyl sepharose hydrophobic 
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interaction chromatography column (HIC) equilibrated with 25mM Tris, pH8, 200M NaCl, 
1M (NH4)2SO4 . Elution was performed in steps at over a gradient of 1-0 M (NH4)2SO4, 25mM 
Tris, pH8, 200mM NaCl (3ml samples). LHD elution was confirmed by SDS page analysis and 
corresponding fractions were pooled together. Pooled sample was dialysed overnight 
against 10L’s dialysis buffer (25mM Tris, pH8, 200mM NaCl) at 4°C. The sample was finally 
concentrated using Vivaspin 50000 MWCO concentrator (Millipore), spinning at 3000 g until 
concentration reached approximately 4 mg/ml. All concentrations were determined by 
absorbance measurement at 280nm. Protein was stored in 1ml aliquots at -20°C until 
further use. 
 
3.2.2.3 Crystallisation of LHD 
 
 Initial screening for crystallisation conditions was completed using a crystallisation 
robot (Phenix, Art Robbins instruments) with PGA Screen (Molecular Dimensions). The 
condition was repeated using the hanging-drop vapour diffusion method, with 3µl drops 
(2µl protein and 1µl mother liquor) against a reservoir (500μl) at 16°C. LHD crystals were 
obtained using 15% PEG 2K MME, 0.3M (NH4)2SO4, 0.1M NaC2H4O2, pH4.6 (Figure 3.2).  
 
3.2.2.4 Data collection  
 
 X-ray diffraction data for LHD was collected at Diamond Light Source (DLS, UK), 
beamline I03. Prior to data collection, LHD crystals were transferred to a cryoprotectant 
solution with 25% (v/v) glycerol for 1 min, and then flash-frozen under a nitrogen stream. 
Data processing and space group determination was performed using MOSFLM version 
7.0.3. 
 
3.2.2.5 Purification of HN serotype D from N-terminal his-tagged LHD 
 
 A 3ml Ni-NTA agarose (Quiagen) drip column was equilibrated with 25mM Tris, 
200mM NaCl, 0.5% n-Octyl-β-D-Glucopyranoside, pH8. 1mg/ml N-terminal his-tagged LHD 
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was loaded “dripwise” onto the column before subsequently washing with 25mM Tris, 
200mM NaCl, 0.5% n-Octyl-β-D-Glucopyranoside, 10mM DTT, pH8. 
 
3.2.2.6 HN domain cloning and expression (serotype A and C) 
 
 Plasmids encoding for LHN serotypes A and C respectively were supplied by Syntaxin 
Ltd. Plasmids were digested sequentially using SalI and HindIII (New England Biolabs) to 
isolate HN domain DNA, HN domain DNA was then purified using agarose gel electrophoresis 
before ligation into the pMAL-c2x vector (NEB, UK). Following conformation of the DNA 
composition through sequencing the vector was transformed into E. coli BL21 expression 
cells for expression.  
 
 HN domain expression was completed as per section 3.2.2.1. The cells were then 
harvested, re-suspended in a minimal volume of 25mM Tris, 500mM NaCl, pH8, 1% Triton 
X-100, 1% Tween 20 and stored at -80oC until further use. 
 
3.2.2.7 HN domain serotype A purification 
 
 Cells were resuspended in 25mM Tris, pH 8, 0.5M NaCl, 1% Triton X-100, 1% Tween 
20 (1g cell paste: 100ml re-suspension buffer) and lysed using a homogeniser (Constant 
Systems Ltd). The lysate was centrifuged 20,000 g for one hour. The supernatant was 
filtered and loaded onto a 20ml Ni2+-charged chelating sepharose column (GE Healthcare). 
Fractions were eluted over an imidazole gradient (0-400mM Imidazole) (25mM Tris, pH8, 
200mM NaCl, 0.5% Triton X-100, 0.5% Tween 20) (Figure 3-8 (A)). The fractions of interest 
were pooled together before adding a solution of 2M (NH4)2SO4 slowly to achieve a final 
(NH4)2SO4 concentration of 0.5M. The sample was filtered before overnight dialysis against 
25mM Tris, pH8, 200mM NaCl, 0.5% Triton X-100, 0.5% Tween 20 at 4°C. The sample was 
loaded onto a Superdex size exclusion column (GE Healthcare) equilibrated with 25mM Tris, 
pH8, 200mM NaCl, 0.5% n-Octyl-β-D-Glucopyranoside to remove previous detergent. 




3.2.2.8 HN domain serotype C purification 
 
 Cells were resuspended in 25mM Tris, pH 8, 0.5M NaCl, 1% Triton X-100, 1% Tween 
20 (1g cell paste: 100ml resuspention buffer) and lysed using a homogeniser (Constant 
Systems Ltd). The lysate was centrifuged at 20,000 g for one hour. The supernatant was 
filtered and loaded onto a 20ml Ni2+ chelating sepharose column (GE Healthcare). Fractions 
were eluted over an imidazole gradient (0-400mM Imidazole) and checked via SDS-page 
electrophoresis for content (25mM Tris, pH 8, 200mM NaCl, 0.5% Triton X-100, 0.5% Tween 
20). The fractions of interest were pooled together and dialysed overnight at 4 °C against 
25mM Tris, pH 8, 200mM NaCl, 0.5% Triton X-100, 0.5% Tween 20.  Ammonium sulphate 
solution was added to the cleaved fusion protein to reach a loading concentration of 0.5M 
before loading onto a phenyl sepharose hydrophobic interaction chromatography column 
(HIC) equilibrated with 25mM Tris, pH8, 200M NaCl, 0.5M (NH4)2SO4 0.5% Triton X-100, 
0.5% Tween 20. Elution was performed at over a gradient of 0.5M- 0M (NH4)2SO4. The 
sample was loaded onto a Superdex size exclusion column (GE Healthcare) equilibrated 
with 25mM Tris, pH8, 200mM NaCl, 0.5% n-Octyl-β-D-Glucopyranoside to remove previous 





3.2.3.1 The purification, crystallization and diffraction of C-terminal His-tagged LHD 
 
 LHD has been successfully expressed, purified and crystallized in an attempt to 
elucidate its three-dimensional structure via X-ray diffraction. 
 
Expression and purification 
 
 Using a pre-optimized expression cell bank provided by Syntaxin Ltd, C-terminal 
His-tagged LHD was expressed in E.Coli BL21 cells. The protein was then successfully 
solubalised via cell lysis (Figure 3-4, C, lane 2). Affinity of LHD’s C-terminal His-tag for a Ni
2+-
charged chelating column allowed immobilization of the protein and removal of a large 
proportion of cellular contaminants (Figure 3-4, C, Lane 3). LHD was then activated via 
proteolytic cleavage using Enterokinase, this evidently broke covalent bonds between the 
LC and HN domains of LHD, seen following reduction of the disulphide linkage known to exist 
between the LC and HN domains, displaying a 50KDa domain (Figure 3-4, C, Lanes 5 and 6). 
Hydrophobic interaction chromatography (HIC) was used to remove contaminants and 
produce approximately 80% pure LHD (Figure 3-4, C, Lane 4).  
 
 The purified protein was subject to automated crystallization screening using over 
500 different crystallization conditions. Finally, crystals of LHD were formed using the sitting 
drop method of crystallization. LHD was crystallised in the presence of 15% PEG 2K MME, 






Figure 3-4 Purification of C-terminal His-tagged LHD for crystallization  
(A) Purification step 1 (PS1); Chromatograph of elution from a Ni2+ chelating column at 
imidazole concentrations of 30, 100 and 250mM respectively. (B) Purification step 2 (PS2); 
Elution from a hydrophobic interaction column (HIC, Phenyl Sepharose) over a gradient of 1 
to 0M (NH4)2SO4. (C) SDS-page summary of purification; Lane 1 Benchmark, 2 Cell lysate, 3 




The protein crystals diffracted to 3.5Å (Figure 3-5, A) before succumbing to 
radiation damage when exposed on the high power synchrotron beam at Diamond Light 
Source, Oxfordshire (DLS, Figure 3-5, B). The radiation damage suffered was too severe to 
record a dataset from which the three-dimensional structure of LHD could be solved. 
Subsequent attempts to reproduce and to further optimise crystallisation conditions were 






Figure 3-5 The crystallization and X-ray diffraction of LHD 
LHD crystals have been formed which diffract focused X-rays at the Diamond light source. 
(A) Crystals of LHD diffract focused X-rays to a resolution of 3.5Å, collected at Diamond Light 
Source (station IO3) (B) Diamond Light Source, Oxford, UK. (C) Crystals of LHD grown in 15% 
PEG 2K MME, 0.3M (NH4)2SO4, 0.1M NaC2H4O2, pH4.6. 
 
3.2.3.2 Using affinity chromatography to separate the Light Chain and HN domain of LHD 
 
 N-terminal His-tagged LHD has been expressed and purified for the purpose of 
separating the HN and LC domains of the protein. Early attempts to separate the domains of 
C-terminal His-tagged LHD using affinity chromatography, failed to produce separation 
(results not shown). By transferring the His-tag to the LC domain (N-terminal), the HN and 
LC domains were separated using a Ni2+ chelating column; both a reducing agent and 
detergent were essential to the separation of the two domains. 
 
 Using a pre-optimized cell bank produced by Syntaxin Ltd, N-terminal His-tagged 
LHD was expressed in E.coli BL21 cells. The protein was then solubilized by lysing cells in the 
presence of high salt buffer (Figure 3-6, D, Lane 2). Affinity of LHD’s N-terminal His-tag for a 
 57 
 
Ni2+ chelating column allowed immobilization of the protein and removal of a large 
proportion of cellular contaminants before eventual elution from the column using 
Imidazole (Figure 3-6 A, C, Lane 3). Following activation, LHD was purified using hydrophobic 
interaction chromatography. Analysis of the eluent through SDS page electrophoresis 
identified two bands. The LHD protein (~100kDa) and an unidentified protein (~50kDa) 
(Figure 3-6, B, D Lane 5). The unidentified 50KDa protein was subsequently removed via 
size exclusion chromatography under non-reducing conditions (Figure 3-6, C, D Lane 7) 
leaving a ~100KDa product (Figure 3-6, D Lane 9). Successful activation was determined 
through SDS-page analysis of LHD under reducing conditions (two ~50KDa domains) and 




Figure 3-6 Purification of N-terminal His-tagged LHD for HN domain purification 
(A) Purification step 1 (PS1); Chromatograph of elution from a Ni-charged chelating column 
at imidazole concentrations of 30, 100 and 250mM respectively. (B) Purification step 2 
(PS2); Elution from a hydrophobic interaction column (HIC, Phenyl Sepharose) over a 
gradient of 1 to 0M (NH4)2SO4. (C) Purification step 3 (PS3); Size exclusion chromatography. 
(D) SDS-page summary of purification; Lane 1, 4, 6 and 8 Benchmark, 2 Cell lysate, 3 PS1 
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250mM elution, 5 PS2 elution, 7 Post activation +10mM DTT, 9 PS3 elution peak 1 (product) 
and 10 PS3 elution Peak 2. 
 
By loading N-terminal His-tagged LHD onto a 3ml Ni-NTA resin column and washing 
the column with a buffer including a reducing agent (10mM DTT) and detergent (0.5% n-
Octyl-β-D-Glucopyranoside) the HN domain was purified. The separation of the light chain 
and HN domains was assessed via western blot (Figure 3-7, A, B). This result was not 
reproducible and following four further attempts to separate the HN domain from the light 




Figure 3-7 Separation of N-terminal His-tagged LHD using Ni-NTA chromatography 
Western blot analysis to identify the HN domain and Light Chain domain of BoNT serotype D  
(A) and (B) respectively; Lane 1 Magic Mark protein weight marker, 2 column flow through, 
3 1ml wash 1, 4 1ml wash 2, 5 1ml wash 3, 6 1ml wash 4, 7 1ml wash 5, 8 1ml wash 6, 9 1ml 
wash 7, 10 1ml wash 8 (anti-light chain and anti-HN domain antibodies used to detect the LC 
domain and HN domain respectively (supplied by Syntaxin Ltd)). 
 
3.2.3.3 Purification of HN domain (serotypes A and C) 
 
 Due to the low yield and poor reproducibility seen during the separation of LHN 
domains, methods to clone, express and purify the HN domain of BoNT serotypes A and C 
were developed (methods 3.2.2.6, 3.2.2.7 and 3.2.2.8 respectively).  
 
 Genetic constructs for the expression of 10 His-tagged HN domains (serotypes A and 
C) were created through the selective endonuclease digestion of LHN expression plasmids, 
separation of digested DNA by agarose gel electrophoresis and ligation into pMAL-c2x 
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vector (NEB, UK). The final sequence was verified via DNA sequencing (Source Bioscience) 
before transformation into BL21 cells (New England Biolabs) and expression. 
 
 Following expression of HN serotypes A and C respectively, the cells were lysed in 
the presence of 1% Triton X-100 and 1% Tween 20 according to literature (Lai et al., 2010). 
Failure to include these detergents in lysis resulted in little to no solubilisation of the HN 
protein (data not shown). 
 
 HN serotype A was purified in three stages; firstly affinity chromatography was used 
to isolate HN from the lysate solution via Ni-Histidine binding, secondly an ammonium 
sulphate cut (increasing concentration of (NH4)2SO4 to approximately 0.5M whilst stirring in 
solution) precipitated many contaminants and finally size exclusion chromatography was 
used to exchange the majority of Triton X-100 and Tween 20 for 0.5% n-Octyl-β-D-
Glucopyranoside. The identity of the HN domain was confirmed thorough western blot 




Figure 3-8 Purification of HN serotype A 
(A) Purification step 1 (PS1); Chromatograph of elution from a Ni2+ chelating column over a 
gradient of 0 to 400mM Imidazole. (B) Purification step 2 (PS2); Size exclusion 
chromatography, peak 1 corresponds to product. (C) SDS-page summary of purification; 
Lane 1 and 4 Benchmark, 2 Cell lysate, 3 PS1 pooled sample, 5 Sample post (NH4)2SO4 cut 6 
PS2 elution peak 1 (product). (D) Western blot analysis of purified protein; Lanes 1 and 3 
Magic Mark protein weight marker, 2 BoNT serotype A Light Chain (control), 4 BoNT 
serotype A HN domain. 
 
 The purification of HN serotype C was completed in three steps; firstly, affinity 
chromatography was used to isolate HN from the lysate solution via NTA affinity 
chromatography; secondly, hydrophobic interaction chromatography removed 
contaminants eluting between a gradient of 0.5 to 0M (NH4)2SO4 (Figure 3-9); finally, size 
exclusion chromatography was used to exchange the majority of Triton X-100 and Tween 
20 for 0.5% n-Octyl-β-D-Glucopyranoside. The purity of the resultant protein was ~60% 
(determined via SDS page analysis, Figure 3-9). The identity of HN serotype C could not be 





Figure 3-9 Purification of HN serotype C 
(A) Purification step 1 (PS1); Chromatograph of elution from a Ni-charged chelating column 
over a gradient of 0 to 400mM Imidazole. (B) Purification step 2 (PS2); Elution from a 
hydrophobic interaction column (HIC, Phenyl Sepharose) over a gradient of 500mM to 0M 
(NH4)2SO4. (C) Purification step 3 (PS3); Size exclusion chromatography. (D) SDS-page 
summary of purification; Lane 1, 4 and 6  Benchmark, 2 Cell lysate, 3 PS1 pooled sample, 5 








 Prior to this investigation only the HN domain of serotype A had been expressed 
and purified. Through isolation of the HN domain, the conditions under which BoNT pore 
formation occurs were investigated (Galloux et al., 2008; Lai et al., 2010). In a bid to further 
understand the serotype specific differences inherent in BoNT pore formation and HN 
domain structure, other HN domains must be expressed and purified for analysis through X-
ray diffraction or functional assay.   
  
 In this chapter I have demonstrated the following; (1) recombinant LHD can be 
expressed, purified and, in one trial, crystallised (crystallisation was not reproducible); (2) It 
is possible to separate the HN and LC domains of LHD by affinity chromatography; (3) The HN 
domain of BoNT serotype A can be cloned, expressed and purified; (4) The HN domain of 
BoNT serotype C has been cloned, expressed and purified for the first time. 
 
3.2.4.1 The purification, crystallisation and diffraction of LHD 
 
 In order to further develop our knowledge of the structure and function of BoNTs 
and their derivatives, LHD was successfully expressed and purified using an optimised 
expression plasmid from Syntaxin Ltd. The protein was purified using a combination of 
affinity and charged based chromatography techniques (Figure 3-4). Furthermore, in one 
trial, crystals were obtained but subsequent attempts to generate crystals were not 
successful. 
 
 During its purification the protein was “activated” by cleaving a sequence of amino 
acids between the HN domain and light chain (LC) in a process designed to emulate post 
synthetic proteolytic cleavage (Masuyer et al., 2009). This activation process facilitates the 
removal of all covalent interaction between the two domains. Activation of BoNT proteins 
is known to be essential for the release and translocation of BoNTs LC domain and 




 LHD was highly soluble and stable at room temperature at concentrations exceeding 
4mg/ml and so was a good candidate for crystallization trials. Through screening over 500 
different crystallization conditions the crystallization of LHD was achieved using the vapor 
diffusion method. The crystals were taken to the DLS in Oxfordshire where they diffracted 
to a resolution of approximately 3.5Å. Unfortunately radiation damage, a common problem 
encountered during X-ray diffraction, irreversibly damaged the crystals preventing a full 
and solvable data set from being obtained (Ravelli and Garman, 2006). These crystallization 
conditions could not be repeated over a period of several months culminating in the 
eventual termination of this project. 
 
3.2.4.2 Separation of HN and LC domains 
 
 LHN proteins contain two domains, namely the light chain domain (LC) and the 
translocation domain (HN). The separation and purification of LHN domains would allow the 
inclusion of HN domains in structural studies for the first time whilst concurrently providing 
new information as to the strength of molecular interactions between HN and LC domains. 
 
 Separating the two domains of LHN requires the reduction of a disulphide bond and 
the breaking of non-covalent intermolecular interactions between the belt region of the HN 
domain and the LC domain (Figure 3-4) (Masuyer et al., 2011; Masuyer et al., 2009). The 
two domains of LHD have been separated by expressing and purifying LHD with a N-terminal 
Histidine tag, reducing the disulphide bond between the two domains and washing with a 
buffer containing a non-ionic detergent (Figure 3-6 and Figure 3-7). This separation was 




Figure 3-10 The three dimensional structure of LHN serotypes A and B as determined by X-
ray crystallography  
The structures of LHA (2W2D, left) and LHB (2XHL, right) have been determined by X-ray 
crystallography. The Light chain (LC) domain of each serotype is highlighted in green and 
the HN domain in blue. Disulphide bonds and belt regions have been labeled using arrows. 
Zn2+ atoms associated with the Zn2+ metalloprotease function of the light chain domain are 
highlighted in red (Masuyer et al., 2011; Masuyer et al., 2009).  
 
  
 The need for a detergent, known to be capable of solubalising some membrane 
proteins (0.5% n-Octyl-β-D-Glucopyranoside), to solubalise HN is evidence of the domains 
hydrophobicity. This further supports the hypothesis that BoNTs HN domain interacts with 
membrane structures (Fischer et al., 2012). 
 
 Unfortunately, this method of separating LHD’s HN domain and LC was not 
reproducible as complete separation of the two domains could not be achieved in four 
further experiments (results not shown). Since, SDS-page analysis of LHD under the same 
reducing conditions shows two separate ~50KDa domains (Figure 3-6), we can conclude 
that the reducing conditions used are sufficient to reduce the inter domain disulphide 
bond. Many other non-covalent intermolecular interactions seen between the LC and HN 
domains of LHN (Figure 3-10) are therefore presumed responsible for the lack of domain 
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separation. This observation was supported by literature examples of the separation of the 
LC domain from the heavy chain domains of BoNT. In these experiments a mixture of 
dithiothreitol and 2M urea was required to separate the domains; under these conditions 
the LC domain was found to be unstable (DasGupta and Foley, 1989). 
 
3.2.4.3 Purification of the BoNT HN domain 
 
  The inherent difficulty found when trying to separate the two domains of LHD lead 
to the decision to separately express and purify the HN domain of BoNT serotypes A and C 
respectively. As discussed, purification of the HN domain is necessary in order to advance 
our knowledge of HN domain specific membrane interactions; through purifying multiple 
serotypes of the HN domain it may be possible to investigate serotype specific differences in 
HN domain physical properties and function for the first time. 
 
 The HN domain of BoNTA has been expressed and purified using a mixture of affinity 
chromatography, ammonium sulphate precipitation and size exclusion. This purification 
was monitored by SDS page and western blot analysis (Figure 3-8). The HN domain of BoNTC 
has similarly been cloned, expressed and purified using a mixture of affinity 
chromatography, hydrophobic interaction chromatography and size exclusion. This is the 
first documented case of HN serotype C expression and purification; the purification was 
deemed successful through analysis by SDS page. Western blot analysis was not 
successfully completed as an antibody capable of accurately recognising the HN domain of 
BoNTC was not available. Certain elements of the purification will be discussed as they 
provide information regarding the physical characteristics of HN domains. 
 
 Literature examples show that in order to solubilise HN proteins, cells that have 
expressed HN must be lysed in the presence of detergent or re-solubilised from urea 
(Fischer et al., 2012; Galloux et al., 2008; Lai et al., 2010).  Both serotypes of HN purified 
here have been successfully solubilised by lysing in the presence of a high concentration of 
detergent (1% Triton X-100 and 1% Tween-20); lysing expressed HN serotypes A and C in the 
absence of detergents prevents the proteins from solubalising (results not shown), 
demonstrating that the HN domain is insoluble following expression.  Aggregation and 
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insoluble expression is common among hydrophobic proteins expressed in E.coli (Kopito, 
2000). The HN domains solubilisation in detergents is evidence that the domains have 
potential to interact with the hydrophobic phospholipid environment present in cellular 
membranes. The decision was made to avoid re-solubalising the proteins using urea to 
avoid denaturing and refolding of the proteins.   
 
 Detergents that form large micells, such as Triton X-100 and Tween-20, are difficult 
to separate from purified proteins as their size does not allow them to pass though 
commonly used dialysis tubing.  Size exclusion was found to be the most efficient method 
of removing Tween-20 and Triton X-100 from the protein sample; the UV absorbance (A260) 
of the detergent allows us to monitor the separation of the protein and detergents through 
UV absorbance during size exclusion chromatography (Figure 3-8, B and Figure 3-9, C) the 





 LHN serotype D has been successfully expressed, purified and crystallised. The 
crystals produced diffracted to a resolution of ~3.5Å, however, due to radiation damage a 
full data set could not be collected and consequently the structure of LHD could not be 
determined.   
 
 In an attempt to purify the HN domain of LHD, the LC and HN domains were 
separated using affinity chromatography. Separation of the two domains requires reducing 
conditions and a non-ionic detergent suggesting that the HN protein possess lipophilic 
characteristics. Due to the lack of reproducibility, this method of HN domain purification 
was discontinued. 
 
 The HN domains of BoNT serotypes A and C were cloned, expressed and purified 
successfully. This is the first reported cloning, expression and purification method of HN 
serotype C. Once again the proteins reliance on detergent to become soluble in an aqueous 








 Botulinum neurotoxin (BoNT) binds specifically to the pre-synaptic terminal of 
motor neurones. Once bound, there is evidence to suggest the toxin is endocytosed inside 
synaptic vesicles (Figure 3-11) (Colasante et al., 2013; Harper et al., 2011; Montecucco et 
al., 1994) (see section 1.5.2.1).  
 
 
Figure 3-11 The endocytosis of gold labeled BoNTA HC domain into synaptic vesicles.  
The location of gold labeled BoNTA HCC domain has been established in hippocampal 
neurons via immuno-electron microscopy. sv, synaptic vesicles; pm, plasma membrane; 
scale bar 100nm (Harper et al., 2011). 
 
 Once inside the synaptic vesicle, BoNT must translocate its catalytically active 
protease domain (light chain) through the endosomal membrane into the cell cytosol. The 
translocation of the light chain is thought to take place though a pore formed by BoNTs HN 
domain, following vesicle acidification (Montecucco et al., 1994). Light chain translocation 
is then thought to be effected by both pH and reducing gradients (Fischer et al., 2009; 
Montal, 2009). 
 
 The way in which BoNTs form pores in vesicular membranes is debated. There are 
two schools of thought, the first argues that only one molecule of BoNT is taken up into a 
vesicle and therefore the translocation of the light chain must occur through a singular 
translocation domain (Colasante et al., 2013); the second states that BoNT forms a 
multimeric pore, thus requiring more than one molecule to be contained within a vesicle 
 68 
 
(Sun et al., 2011). Both possibilities are plausible and are supported by experimental 
evidence (see sections 1.5.2.4 for evidence and arguments).  
 
 There are currently two assays thought to be capable of quantifying BoNT pore 
formation. These assays are the patch clamp assay and vesicle leakage assay.  
 
Patch clamp assay 
 
 A patch clamp assay involves excising a small segment of Neuro 2A or PC12 cell 
membrane onto the end of a highly polished glass syringe. Through measuring the sodium 
ion conductance through the excised membrane segment, the pore forming nature of 
proteins has been qualified (Brunger et al., 2007; Fischer et al., 2008a; Fischer and Montal, 
2006; Fischer and Montal, 2007a; Fischer and Montal, 2007b; Fischer et al., 2008b; Fischer 
et al., 2009; Fischer et al., 2012). 
 
 
Figure 3-12 The patch clamp technique.  
A glass micropipette with a tip diameter of ∼1μm is moved onto the cell to form a high-
resistance seal with the cell. Suction is applied and a high-resistance seal is obtained 
between the pipette and cell. The membrane underlying the pipette aperture is then 
broken to enable the amplifier to control the voltage across the whole of the cell 






Vesicle leakage assay: 
 
 Vesicle leakage assays quantify the release of a fluorescent marker from inside 
spherical, unilamellar, liposomes (also known as vesicles) into the “extravesicular” 
environment upon interaction with pore forming proteins or peptides. The fluorescent 
marker is quantifiable upon release due to a change in the marker’s physical environment, 
resulting in a change in its potential to fluoresce under experimental conditions. The vesicle 
leakage technique has been used to detect the pore forming potential of Botulinum 
neurotoxins and their derivatives, previously confirming that BoNT membrane interaction is 
pH dependent (Fu and Singh, 1999; Galloux et al., 2008; Lai et al., 2010).  
  
 
Figure 3-13 The Vesicle Leakage Assay  
Highly concentrated self quenching dye is encapsulated inside lipid vesicles. 
Permeabilization of the vesicle membrane will cause the release of vesicular dye, this 
release will be recorded as an increase in fluorescence. 
 
Here we show the development of the vesicle leakage assay into a 96 well assay. 






Figure 3-14 Production of Sulforhodamine B loaded lipid vesicles  
A simplified protocol for creating vesicles (100nm diameter) which encapsulate 50mM 
Sulforhodamine B dye.  
 
3.3.2.1 Vesicle creation  
 
Large unilamellar vesicles were prepared as follows: 
 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC) and 1,2-dioleoyl-sn-glycero-3-
phospho-(-1-race-glycerol) (DOPG) (Avanti Polar Lipids, INC) were solubilised in chloroform 
(20mg/ml) before they were mixed at a ratio of 3:1 (300µl DOPC: 100µl DOPG) in a glass 
vial. The solution was dried under a nitrogen jet before the glass vial was placed in a 
desiccator at room temperature for 1.5 hours to remove excess chloroform. Then, 1ml of 
25mM Tris, 50mM NaCl, 50mM Sulforhodamine B (SRB, pH7) buffer was used to re-suspend 
the phospholipids by vortex for 2mins. The mixture was transferred into a cyro-vial and 
frozen at -80°C before thawing at 42°C (three times). A mini-extruder (Avanti Polar Lipids, 
INC) was heated to 50°C (to reduce membrane stability) before it was assembled with a 
0.1µm membrane and used to extrude the lipid/buffer mixture ten times. The resultant 
Mix Phospholipids in Chloroform 
Dry Phospholipid Mixture 
Create vesicles by Re-Suspending Phospholipids in SRB Buffer by Vortex 
Freeze/Thaw cycles (x3) to Increase the Proportion of SRB Loaded 
Vesicles 
Extrude Mixture to Regulate Vesicle Size 
Separate Vesicles From Free Dye using Size Exclusion 
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mixture was then loaded onto a HiPrep 26/10 desalting column equilibrated with assay 
buffer. The extravesicular dye was then separated from the formed large unilamellar 
vesicles (LUV’s) at a flow rate of 0.8ml/min. Samples containing LUV’s were pooled and 
dialysed in assay buffer. 
 
3.3.2.2 Vesicle concentration/calibration assay 
 
 Following LUV purification a calibration assay was used to determine vesicle 
concentration. 
 
 To evaluate the concentration at which the manufactured LUV solution had a low 
level of background fluorescence, LUV stock solution was diluted in assay buffer to 
concentrations of 30%, 20%, 10%, 5% and 0% respectively. 250µl of each concentration was 
mixed to ensure LUV suspension in three individual wells on a black 96-well plate (Costar) 
before excitation and emission wavelengths of 565nm and 585nm respectively were used 
to measure SRB fluorescence with a Flexstation 3 plate reader (Molecular Devices). To 
measure the maximum possible florescence, 25µl of 1% Triton X-100 in assay buffer was 
added to each well of the 96 well plate and mixed; the plate was then re-read using the 
same reading protocol. The LUV concentration which demonstrates the lowest level of 
background florescence and the highest level of maximum fluorescence was chosen for 
vesicle leakage experiments. 
 
3.3.2.3 Vesicle leakage assay 
 
 Vesicle leakage assays are performed to measure the disruption of vesicle 
membranes through tracking the release of SRB contained within those membranes. The 
leakage of SRB from LUV’s was determined by measuring an increase in SRB fluorescence.  
 
 200µl of LUV solution (working concentration) was pipetted into black 96-well 
plates (Costar) where it was mixed with 40µl of test solution. Finally 10µl of pH regulating 
buffer (phosphate-citrate buffer) was added to determine the pH of the experiment. 
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Phosphate-citrate buffer was formulated for each experiment by titrating 1M dibasic 
sodium phosphate and 0.5M citric acid in a water bath at assay temperature; the pH 
change of assay buffer was then determined following the addition of 1ml phosphate-
citrate buffer to 24ml assay buffer at assay temperature. The 96 well plate was placed in 
the Flexstation 3 reader where it was subjected to the following protocol at a temperature 
which was set manually; fluorescence was measure every 25 seconds at excitation and 
emission wavelengths of 565nm and 585nm respectively; the plate was shaken for 5 
seconds between every read. The final point of each assay was read after addition of 25µl 
of assay buffer containing Triton X-100 to each well and mixing with pipette (x3), this stage 
causes 100% vesicle leakage (Fmax).  
 
3.3.2.4 Data analysis 
 
% Vesicle leakage: 
 
 The raw fluorescent data was converted to PDA data files and processed using 
Microsoft Excel. To determine dye eluted following protein addition as a percentage of 
total vesicle release, F(t)norm is calculated as a percentage of the maximum fluorescence 
observed following 0.1% Triton X-100 addition using the following equation,  
 
F(t)norm = (F(t) – F(0))/(Fmax – F(0))x100, 
 F(0)  is the fluorescence level before protein addition, F(t) is the fluorescence at time 
point (t) and Fmax is the fluorescence after addition of 1% Triton-X100 before the final 





3.3.3.1 Sulforhodamine B dye self quenches at a high concentration 
 
 To set up a vesicle leakage assay, lipid vesicles must be loaded with a chemical 
marker which is differentially detectable in two different environments (1) when inside lipid 
vesicles and (2) when in extravesicular media. Sulforhodamine B (SRB) dye is often used in 
vesicle leakage assays as its fluorescence self quenches at a high concentration (when 
inside lipid vesicles). Here we assess the concentration dependent fluorescence of 5mM-
50nM SRB at 37°C, using excitation and emission wavelengths of 565nm and 585nm 
respectively.   
 
 SRB fluorescence at 585nm increases proportionally with SRB concentration over a 
concentration range of 20µM-50nM.  At concentrations greater than 20µM, SRB 
fluorescence was inhibited by SRB self quenching. A concentration of 0.1% Triton X-100 
appears to have little or no effect on the florescence of SRB dye. 
 
 An SRB concentration of 50mM was used in all further experiments because (1) 
concentrations of SRB greater than 5mM have been shown to quench its fluorescence at an 
excitation wavelength of 565nm (Figure 3-15) and (2) published vesicle leakage assays use a 





Figure 3-15 Sulforhodamine B dye self-quenches at a high concentration  
(A) 96 well plate layout of SRB assay. (B) Assay formulation and Flexstation 3 settings (C) 
Dose dependent fluorescence of Sulforhodamine B dye (5mM- 50nM) with (■) and without 
(●) 0.1% Triton X-100. (n=1).  
 
3.3.3.2 SRB loaded lipid vesicles are stable at pH4 and pH8  
 
 The stability of phospholipid vesicles, loaded with SRB containing buffer, at both 
neutral and acidic pH is essential for the development of an assay to measure pH 
dependant vesicle leakage. Vesicle stability has been determined at both neutral and acidic 
pH by loading vesicles composed of 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC) and 
1,2-dioleoyl-sn-glycero-3-phospho-(-1-race-glycerol) (DOPG) (3:1 v/v) with 50mM SRB 
buffer and measuring vesicle leakage at pH 8 and pH 4 respectively (Figure 3-16) over a 
time course of 15 minutes. The final time point displays complete vesicle lysis after addition 
of 12.5µl 1% Triton X-100 buffer. 
 
 There is no obvious destabilization of vesicles at pH8 or pH4. The addition of Triton 




Figure 3-16 Sulforhodamine B loaded lipid vesicles are stable in solution at pH8 and pH4 
(n=1)  
(A) 96 well plate layout. (B) Assay formulation and Flexstation 3 settings. DOPC/DOPG (3:1 
v/v) lipid vesicles loaded with SRB buffer (25mM Tris, 50mM NaCl, 50mM SRB, pH8) were 
assessed for their stability at (C) pH8 and (D) pH4 for 15 minutes. 12.5µl 1% Triton X-100 
was added to each well to show 100% vesicle lysis. 
 
3.3.3.3 Dehydration effects can be minimized by increasing assay volume 
 
 The effect of dehydration at 37°C has been analyzed using well volumes of 100µl 
and 200µl respectively over a time course of 3.5 hours. Vesicle stability over this time 
course was monitored at pH8 and pH4 respectively (Figure 3-17). 
 
 A 100µl well volume displays a decrease in fluorescence in both pH8 and pH4 assay 
buffers (100µl to ~70µl) over a 3.5 hour period. Concurrently, a 200µl well volume shows a 






Figure 3-17 Increasing vesicle well volume from 100µl to 200µl reduces the impact of well 
dehydration (n=1)  
(A) 96 well plate layout. (B) Assay formulation and Flexstation 3 settings. Vesicles loaded 
with 50mM SRB buffer were tested for stability at well volumes of 100µl and 200µl 
respectively. Vesicle stability is displayed at (C) pH8 and (D) pH4 (37ºC). 12.5µl (C) or 25µl 
(D) 1% Triton X-100 was added to each well to show 100% vesicle lysis. 
 
 
3.3.3.4 Mixing 96 well plates is essential when measuring vesicle-protein interactions 
 
 The purpose of a vesicle leakage assay is to quantify the leakage of vesicle contents 
following vesicle-protein or vesicle-peptide interactions; vesicle leakage is measured 
through an increase in SRB florescence (a consequence of SRB leaving lipid vesicles). Here 
we attempt to further optimize the conditions under which protein-vesicle interactions can 





 Vesicles loaded with 50mM SRB dye were formed and diluted in pH4 assay buffer 
(see materials and methods). 50µl LHB was then added to each well in order to create LHB 
concentrations of 1, 0.1 and 0.01µM respectively at time 0. SRB florescence was measured 
over a time course of 900 seconds with and without assay agitation (Figure 3-18 C and D 
respectively). 
 
 In the absence of agitation, there was no detectable vesicle leakage caused by LHB 
addition. Following plate mixing an increase in fluorescence was detected at a LHB 
concentration of 1µM (Figure 3-18, D). This increase in fluorescence is consistent with 
vesicle disruption and SRB dye leakage (Figure 3-18).  No increase in fluorescence was 
detected when the same experiment was completed at pH7 (results not shown) suggesting 
that a low pH is necessary for LHN proteins to interact with vesicular membranes. 
  
 
Figure 3-18 Plate mixing is required to measure vesicle leakage (n=1)  
(A) 96 well plate layout (B) Assay conditions and Flexstation 3 protocol settings. The 
addition of various LHB concentrations (1µM, 0.1µM and 0.01µM respectively) to vesicles 
was completed with (D) and without (C) a 96 well plate mixing protocol. 25µl 1% Triton X-





3.3.3.5 Determining working vesicle concentration 
 
 The concentration of dye loaded vesicles, used in vesicle leakage assays, must be 
consistent for vesicle leakage experiments to be comparable. To regulate the concentration 
of dye loaded vesicles, the fluorescence of vesicle preparations was measured in the 
presence and absence of 1% Triton X-100. Finally a vesicle concentration was chosen with 
fluorescence values of <20,000 RFU and >40,000 RFU (with and without 1% Triton X-100 
respectively). 
 
 Vesicles loaded with 50mM SRB dye are diluted in assay buffer at concentrations of 
30, 20, 10 and 5% respectively before loading onto a 96 well plate (250µl well volume). The 
fluorescence of the vesicles was determined at 0% vesicle leakage (minimum vesicle 
fluorescence) and at 100% vesicle leakage (after the addition of Triton X-100). An example 
of this comparison is displayed in Figure 3-19.     
 
   
 
Figure 3-19 Calibration assay to regulate vesicle concentration (n=1)  
(A) 96 well plate layout (B) Assay conditions and Flexstation 3 protocol (C) Vesicle 
concentrations of 30, 20, 10, 5 and 0% were assed for fluorescence  with and without the 




3.3.3.6 Pre-incubation of 96 well plates before testing 
 
Figure 3-20 Pre-incubation at 37°C increases the initial rate of vesicle leakage (n=3)  
(A) 96 well plate layout (B) Assay conditions and Flexstation 3 protocol (C) The addition of 
1µM LHB concentration to vesicles was completed with (D) and without (C) pre-incubation 
of the 96 well plate at 37°C for 10 minutes before testing. 25µl 1% Triton X-100 was added 
to each well to show 100% vesicle lysis (not shown). 
 
 
 In order to better regulate the temperature at which vesicle leakage assays are 
initiated, a pre-incubation step was introduced. All elements used in the assay were pre-
incubated at 37°C for 10 minutes prior to commencing the assay. 
 
 Here vesicles loaded with 50mM SRB dye were formed and diluted in pH4 assay 
buffer. Once prepared, solutions were either incubated for 10 minutes at room 
temperature (Figure 3-20, C) or at 37°C in the Flexstation 3’s loading tray (Figure 3-20, D). 
50µl LHB was then added to each well in order to create a final concentration of 1µM at 




 The pre-incubation of assay solutions before assay initiation evidently increased the 
initial rate of vesicle leakage. An assay initiated at room temperature demonstrated vesicle 






 Vesicle leakage is a well-known technique that has previously been used to 
determine the pore forming properties of Botulinum neurotoxins (BoNTs) and their 
derivatives (Galloux et al., 2008; Lai et al., 2010). Here a 96-well vesicle leakage assay has 
been developed to provide a quick and efficient way of measuring the interaction of BoNT 
proteins and their derivatives with synthetic phospholipid membranes. The qualities 
essential for setting up a vesicle leakage assay are discussed below.  
 
3.3.4.1 Generating large unilamellar vesicles  
  
 The first step of creating a vesicle leakage assay is deciding on the composition of 
the liposome. Ideally the vesicles created in-vitro should mimic those which endocytose 
BoNT into the presynaptic terminal. This would involve understanding the composition of 
naturally occurring synaptic vesicles (see section 1.5.4 for synaptic vesicle composition) 
then optimising a synthetic phospholipid mixture to closely mimic the natural vesicles. 
However, due to time constraints, for this study we relied on published, peer-reviewed 
papers detailing vesicle leakage assays used to detect BoNT induced vesicle leakage and 
used phospholipid mixtures reported as suitable in those papers. 
 
 A phospholipid mixture of 75% DOPC and 25% DOPG (Figure 3-21) was decided 
upon based on information available in literature (Lai et al., 2010). This mixture of 
phospholipids has been used to determine pore formation by vesicle leakage for both 
proteins and peptides at various pH conditions and temperatures. Furthermore a 
DOPC/DOPG vesicle leakage assay has previously been used to determine the pore 





Figure 3-21 DOPC and DOPG phospholipids are used to create large unilamellar vesicles 
(LUV’s)  
DOPC and DOPG phospholipid molecules are displayed above along with their molecular 
formula and molecular weight.  
 
 DOPC/DOPG vesicles contain phospholipids with neutral head groups (DOPC) and 
phospholipids with anionic head groups (DOPG). Increasing the percentage of 
phospholipids with anionic head groups in vesicles has been shown to increase the 
interaction of vesicles with BoNT/A (Galloux et al., 2008) suggesting that increasing the 
surface charge of membranes attracts BoNT molecules. The ratio of DOPC:DOPG in vesicle 
membranes was ultimately chosen to replicate a successful vesicle leakage assay assessed 
to show BoNT pore formation in literature (Lai et al., 2010).  
 
3.3.4.2 Loading large unilamellar vesicles with dye 
  
 Vesicle leakage experiments work on the premise that it is possible to measure the 
release of intra-vesicular compounds in a quantitative manner following vesicle membrane 
disruption. In order to achieve this, the intravascular compound must have the following 
properties. 
 
1. It must be water soluble. 
 
2. It must be possible to form vesicles which trap the compound. 
 
3. When encapsulated in the vesicles it must be possible to separate the loaded 




4. Whether or not the compound is contained within vesicles must be easily 
detectable. 
 
5. The compound’s fluorescence must not be affected by 0.1% Triton X-100 in 
solution. 
 
 Sulforhodamine B (SRB) satisfies the above criteria. It is highly water soluble and 
concurrently lipophilic. When vesicles are formed in the presence of SRB, the dye is seen to 
be encapsulated and stable inside vesicles (Figure 3-16). Vesicles loaded with SRB dye adopt 
a red colour making them easily identifiable. 
 
  SRB loaded vesicles were easily separated from excess SRB buffer using size 
exclusion chromatography. Following a four hour dialysis period, no dye leaked out of the 
vesicles into the dialysis buffer. This suggests that the liposome’s produced are stable and 
that size exclusion chromatography is sufficient to fully remove extra vesicular dye.   
 
 So that we can determine an increase in SRB fluorescence upon vesicle disruption, 
the vesicles must be loaded with a concentration of SRB that is known to quench 
florescence. In order to determine the concentration dependence of SRB fluorescence the 
self quenching nature of SRB was examined (SRB has absorbance and emission wavelengths 
of 565nm and 585nm respectively). Figure 3-15 shows that a 5mM concentration of SRB is 
sufficient to quench the dyes fluorescence to basal levels. For this reason vesicles were 
loaded with a concentration of SRB greater than 5mM during assay development, the 
concentration chosen for subsequent experiments was 50mM (based on published studies). 
  
3.3.4.3 Vesicle stability 
 
 After determining that lipid vesicles could be made to encapsulate SRB dye at a 




 BoNTs and their derivatives are known to need acidic conditions to translocate 
(Montecucco et al., 1994; Mushrush et al., 2011). The vesicles produced must therefore be 
stable at low pH for pore formation to be assessed. Figure 3-16 shows vesicles were stable 
at pH8 and pH4 at various concentrations. This figure also shows that, after the addition of 
0.1% Triton X-100, fluorescence increased. This observation is further evidence that SRB 
self-quenches at high concentration (in vesicles) and, when diluted through vesicle leakage, 
its observed fluorescence increases.  
 
 In Figure 3-17 the effect of assay dehydration on background florescence has been 
assessed. Here we see that by increasing the well volume from 100µl to 200µl it is possible 
to reduce the effect of dehydration on baseline fluorescence. At 37⁰C the 100µl well 
volume decreases over time due to dehydration, consequently, the concentration of SRB in 
solution increases, resulting in a reduction in SRB fluorescence. Dehydration also occurs at 
the higher 200µl well volume, however, the volume reduction is proportionally lower 
resulting in a lower SRB concentration increase and no reduction in fluorescence. 
  
3.3.4.4 Regulating vesicle concentration 
 
Vesicle concentration must be regulated so that assays completed with different 
batches of vesicles are comparable. Figure 3-19 shows how vesicle concentration can be 
regulated by assessing the difference between baseline vesicle fluorescence and lysed 
vesicle fluorescence. As the concentration of vesicles is reduced, the baseline florescence 
increases due to a reduction in SRB self-quenching; concurrently, the fluorescence of SRB 
from lysed vesicles (using Triton X-100) is reduced as the final SRB concentration in solution 
is lowered.  
 
Vesicle calibration was completed for every batch of vesicles produced. The vesicle 
concentration chosen had a baseline fluoresce value below 20,000 RFU and a lysed vesicle 






 In order to better regulate the temperature at which the assay is initiated, a 10 
minute pre-incubation step was added to the assay protocol. Figure 3-20 displays the effect 
of pre-incubating the assay reagents for 10 minutes at 37°C prior to initiation. Pre-
incubation has evidently had the effect of increasing the initial rate of vesicle leakage and 
the maximum vesicle leakage achieved by 1µM LHB.  
 
 
3.3.5 Conclusion  
 
 Here we have successfully demonstrated the creation of a 96 well vesicle leakage 
assay capable of assessing protein induced vesicle leakage in a quick and efficient manner. 
 
 Lipid vesicles have been successfully prepared encapsulating a self-quenching 
concentration of SRB dye. The resultant vesicles were stable under conditions of low pH 
and high temperature. Vesicle leakage can only be determined following interaction with 
proteins at acidic pH and when mixed. 
 
 The concentration of SRB loaded lipid vesicles can be assessed prior to vesicle 






3.4 Removal of botulinum neurotoxin’s receptor binding domain affects the protein’s 




 It is well recognised that Botulinum toxins have the ability to form pores in 
phospholipid membranes (Montal, 2010). To better understand the structure and function 
of Botulinum toxins and their domains, I have developed a 96-well vesicle leakage assay to 
analyse BoNT and LHN pore forming potential in accordance with published results.  Here 
we set out to analyse vesicle leakage potential to measure protein pore formation and 
discuss how BoNT and LHN induced vesicle leakage may allow us to learn more about the 
activity and functional characteristics of these proteins. 
 
3.4.1.1 A comparison of BoNT serotypes A and E 
 
As discussed, both BoNT serotypes A and E block exocytosis of neurotransmitters 
by cleaving SNAP-25, a protein known to be essential to the fusion of synaptic vesicles to 
the pre-synaptic membrane (Agarwal et al., 2004). However, major differences have been 
identified, both structurally and functionally, between the two serotypes.   
 
Functionally, BoNTE enters cultured neurones more quickly than BoNTA, has a lower 
potency, cleaves SNAP-25 at a different recognition site and ultimately acts faster to inhibit 
transmission at the neuromuscular junction (NMJ) (Wang et al., 2008a). BoNTE also totally 
inhibits vesicular fusion, in this respect it is similar to BoNTs (such as B, C, D and F) which 
cleave VAMP or Syntaxin and unlike BoNTA inhibition which can be rescued (for example by 
increasing intracellular Ca2+) (Sakaba et al., 2005). Studies have also shown that inhibition of 
NMJ transmission caused by BoNTE has a shorter recovery time than that caused by BoNTA 
(30-45 days in comparison to more than 90 days in the human Extensor Digitorum Brevis 
Muscle (EDB) respectively) (Kumaran et al., 2009). 
 
Structurally, although the individual domains of BoNTE are similar to those of BoNTA 
the domain organisation is different (see Figure 1-3). BoNTA’s catalytic (LC) and binding 
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domains (HC) flank the long translocation domain with no apparent interactions between 
them. In contrast, the LC and HC domains of BoNTE appear on the same side of the 
translocation domain and interact with one another, resulting in a tight globular molecule, 
with each domain having an interaction with the other two domains. It has been 
hypothesised that the high translocation rate attributed to BoNTE is a result of the HN and 
LC domains high sensitivity to pH changes due to the HN domains proportionately higher 
exposure to solvent than in BoNTA (Kumaran et al., 2009). 
 
The different functional characteristics of BoNTA and BoNTE have been shown to be 
transferable though creation of BoNT chimeras comprised of functional domains from both 
serotypes. When a chimera was created composed of the LC and HN domains of BoNTE and 
HC domain of BoNTA, the protein was shown to possess the fast translocation characteristics 
of BoNTE. Concurrently, a chimera composed of the LC and HN domains of BoNTA and the HC 
domain of BoNTE showed translocation rates comparable to that of BoNTA. This not only 
highlights BoNT domain functionality and differences between the functional 
characteristics of BoNT serotypes but also suggests that a protein composed only of the HN 
and LC domain may be capable of displaying pore formation properties representative of 
those  of the full length BoNT toxin (Wang et al., 2008b). 
 
3.4.1.2 BoNT serotypes A and E form pores in lipid membranes 
 
Through electrophysiological methods, such as patch clamp assays it has been 
concluded that BoNT serotypes A and E form pores in lipid membranes under acidic 
conditions. Membranes from synthesised lipid bilayers (BoNTA), PC12 cells (BoNTA) and 
Neuro 2A cells (BoNTA and BoNTE) have all been assessed for their potential to permit BoNT 
membrane permeation which is thought to be as a consequence of BoNT HN domain pore 
formation (Fischer et al., 2008a; Monta et al., 1992; Oblatt-Montal et al., 1995).  
 
Although the manner in which a translocation pore is created is disputed, the field 
generally agrees that the HN domain of BoNT and an acidic pH are essential for the 
formation of a translocation pore. However, the role of the receptor binding domain (HC) in 
pore formation is less well understood. In some models the HC domain recognition of pre-
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synaptic membrane receptors is thought to be essential to pore formation (BoNTB) (Sun et 
al., 2011; Sun et al., 2012), in others the HC domain is considered as completely non 
essential to the formation of a pore (BoNTA and LHA) (Chaddock and Marks, 2006; Chaddock 
et al., 2004; Chaddock et al., 2000a; Chaddock et al., 2000b; Fischer et al., 2008b).  
 
The vesicle leakage assay described in section 3.3 provides us with a tool with 
which we can potentially further evaluate BoNT and LHN pore formation. In this chapter we 
evaluate positive and negative pore forming controls in order to evaluate whether this 
assay is a useful tool to evaluate pore formation at acidic pH. Following this we analyse the 
concentration, pH and temperature dependant nature of BoNT and LHN induced vesicle 
leakage in order to answer the following questions. (1) Can LHN proteins form pores in 
vesicle membranes? (2) Does removing the HC domains from BoNT affect the rate at which 
it may interact with vesicle membranes? And (3) Do BoNTA and BoNTE form pores at 
different rates respectively and does this compliment evidence that BoNTE translocates at a 





3.4.2 Materials and Methods 
 
3.4.2.1 Vesicle creation  
 
See section 3.3.2.1. 
3.4.2.2 Vesicle concentration/calibration assay 
 
 Following LUV purification a calibration assay was used to determine vesicle 
concentration. 
 
 To evaluate the concentration at which the manufactured LUV solution had a low 
level of back ground fluoresce, LUV stock solution was diluted in assay buffer to 
concentrations of 30%, 20%, 10%, 5% and 0% respectively. 250µl of each concentration was 
mixed in three individual wells on a black 96-well plate (Costar) before excitation and 
emission wavelengths of 565nm and 585nm respectively were used to measure SRB 
fluorescence with a Flexstation 3 plate reader (Molecular Devices). To measure the 
maximum possible florescence, 25µl of 1% Triton X-100 in assay buffer was added to each 
well of the 96 well plate and mixed; the plate was then re-read using the same reading 
protocol. The LUV concentration which shows the lowest level of background florescence 
and the highest level of maximum fluoresce was chosen for vesicle leakage experiments. 
 
3.4.2.3 Vesicle leakage assay 
 
 Vesicle leakage assays were performed to measure the disruption of vesicle 
membranes through tracking the release of SRB buffer contained within those membranes. 
The leakage of SRB buffer from LUVs was determined by measuring an increase in SRB 
fluorescence by excitation and emission wavelengths of 565nm and 585nm respectively 
using a Flexstation 3 plate reader.  
 
 200µl of LUV solution (working concentration) was pipetted into black 96-well 
plates (costar) where it was mixed with 40µl of test solution. Finally 10µl of pH regulating 
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buffer (phosphate-citrate buffer) was added to set the pH of the reaction. The plate was 
placed in the Flexstation 3 reader where it was subjected to the following protocol at a 
temperature which was set manually; fluorescence was measure every 25 seconds at 
excitation and emission wavelengths of 565nm and 585nm respectively; the plate was 
shaken for 5 seconds between every read. The final point of each assay was read after 
addition of 25µl of assay buffer containing Triton X-100 to each well and mixing with 
pipette (x3), this stage causes 100% vesicle leakage (Fmax).  
 
3.4.2.4 Data analysis 
 






3.4.3.1 Non-pore forming proteins show vesicle leakage at acidic pH 
 
To qualify that vesicle leakage was a result of protein or peptide induced pore 
formation, both pore forming and non-pore forming protein controls were assessed for 
vesicle leakage at pH7 and pH4.  GALA is a pore forming peptide which has been reported 
to cause vesicle leakage at acidic pH (Nicol et al., 1999); BSA, Transferrin and the LC domain 
of BoNTA (LCA) are considered non-pore forming proteins at pH7 and pH4. 
 
1µM GALA, BSA, Transferrin and LCA show no appreciable vesicle leakage at pH7 
(Figure 3-22, A, B); however, 1µM concentrations of all proteins and peptides tested 
showed vesicle leakage at pH4 (Figure 3-22, C, D). The assay therefore reported pH 
dependent effect of proteins on lipid membranes but did not distinguish between known 
pore forming proteins and proteins with no known pore forming ability.  This suggested the 
assay did not specifically report formation of stable, protein lined channels. 
 
Although we are not confident that this assay measured only stable, protein lined 
pores, it did measure some physical property, possessed by a protein, that is related to 
insertion into (and disruption of) lipid bilayers. This property is likely to be related to, and to 




Figure 3-22 Positive and negative control proteins show vesicle leakage at pH4.  
Vesicle leakage is measured over a time course of 1000 seconds at 37°C at either pH4 or 
pH7 (A) Vesicle leakage induced by the addition of 1µM GALA at pH7 (n=3). (B) Vesicle 
leakage induced by the addition of 1µM LCA, Transferrin and BSA respectably at pH7 (n=3). 
(C) Vesicle leakage induced by the addition of 1µM GALA at pH4 (n=3). (D) Vesicle leakage 





% Vesicle leakage at 1000 
seconds 
   
GALA 222.75 62.93 
LCA 281.00 55.99 
Transferrin  489.55 62.62 
Bovine Serum Albumin (BSA) 151.03 63.65 





3.4.3.2 Botulinum neurotoxins and LHN derivatives cause vesicle leakage in a 
concentration dependent manner 
 
The concentration dependent manner in which Botulinum neurotoxins and LHN 
molecules cause vesicle leakage was assessed using a 96-well vesicle leakage assay. Vesicle 
leakage induced by 1, 0.1, 0.01 and 0.001µM concentrations of BoNTA, BoNTE, LHA and LHE 
was assessed at pH7 and pH4 respectively. 
 
BoNTA and LHA demonstrate vesicle leakage in a concentration dependent manner 
at pH4. At 1 and 0.1µM, BoNTA induces a faster rate of vesicle leakage in comparison to LHA, 
demonstrated by T50% values of 182.16 and 394.24 to 330.86 and 467.33 seconds 
respectively. 
 
BoNTE and LHE both induce vesicle leakage in a concentration dependent manner at 
pH4; the rate at which these proteins do this is generally very similar. For example, the 
vesicle leakage caused by 1µM BoNTE and LHE is similar with T50% values of 243.15 and 
193.58 seconds respectively. Some specific differences were recognized, including at a 
concentration of 0.01µM where BoNTE demonstrates a faster rate of vesicle leakage than 
LHE with T50% values of 590.55 and 709.01 seconds respectively.  
 
The rate of vesicle leakage induced by a 0.01µM concentration of BoNTA and BoNTE 
at pH4 shows a definable difference between the two serotypes potential to cause vesicle 
leakage. BoNTE demonstrates a T50% value of 590.55 seconds whereas BoNTA does not 
reach 50% vesicle leakage over the 1000 second time course.   
 




Figure 3-23 Removing the HC domain of BoNT serotypes A and E effects vesicle leakage in 
a concentration dependent manner  
Vesicle leakage is measured over a time course of 1000 seconds at 37°C (pH4) (A) Vesicle 
leakage induced by 1, 0.1, 0.001 and 0.0001µM BoNTA respectively (n=3). (B) Vesicle 
leakage induced 1, 0.1, 0.001 and 0.0001µM LHA respectively (n=3). (C) Vesicle leakage 
induced by 1, 0.1, 0.001 and 0.0001µM BoNTE respectively (n=3). (D) Vesicle leakage 



















leakage at 1000 
seconds 
BoNTA 1 182.16 67.99 
 0.1 394.24 63.25 




BoNTE 1 243.15 67.08 
 0.1 303.67 63.664 




LHA 1 330.86 64.361 
 0.1 467.33 61.32 




LHE 1 193.58 68.60 
 0.1 329.38 62.98 




Table 3-3 Summary of the rate at which BoNTA, BoNTE, LHA and LHE cause vesicle leakage 
over a concentration range of 1 to 0.001µM at pH4 
 
 
3.4.3.3 The rate at which BoNT and LHN proteins interact with lipid vesicles is pH 
dependent 
 
Botulinum neurotoxins are known to require a low pH to form pores in membranes 
(Montecucco et al., 1994). Here we investigate the role of the receptor binding domain in 
modulating pH dependency of vesicle leakage induced by BoNTA, BoNTE, LHA and LHE whilst 
varying the pH level at which the interaction occurs. 
 
The rate of vesicle leakage induced by the addition of 0.05µM BoNTA, BoNTE, LHA 
and LHE is reduced by increasing the extra-vesicular pH (Figure 3-24). Removing the HC 
domain of BoNTA has the effect of reducing the rate of vesicle leakage achieved at pH3, 4 
and 4.5 (Figure 3-24 A and B). In contrast to serotype A, removing the HC domain of BoNTE 
did not have a pronounced effect on the rate of vesicle leakage initiated at pH3, 4 and 4.5. 
The most notable difference between BoNTE and LHE induced vesicle leakage was seen at 
pH4 with T50% values of 432.16 and 455.88 seconds respectively. A striking difference 
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between BoNT serotype A and serotype E proteins was that serotype E caused vesicle 
leakage at pH5 whereas serotype A did not. Leakage caused by serotype E is less pH 
dependent than that caused by serotype A. 
 
 
Figure 3-24 Removing the HC domain of BoNT serotypes A and E affects the rate of vesicle 
leakage at pH 3-7.  
Vesicle leakage is measured over a time course of 1000 seconds at 37°C following the 
addition of 0.05µM BoNT and LHN serotypes A and E. (A) Vesicle leakage induced by 0.05µM 
BoNTA at pH 3, 4, 5, 6 and 7 respectively (n=3). (B) Vesicle leakage induced by 0.05µM LHA 
at pH 3, 4, 5, 6 and 7 respectively (n=3). (C) Vesicle leakage induced by 0.05µM BoNTE at pH 
3, 4, 5, 6 and 7 respectively (n=3). (D) Vesicle leakage induced by 0.05µM LHE at pH 3, 4, 5, 6 











 pH T50% 
(Seconds) 
% Vesicle 
leakage at 1000 
seconds 
BoNTA 3 157.77 61.22 
 4 606.45 54.47 




 6  27.88 
 7  27.46 
BoNTE 3 168.19 66.17 
 4 432.16 62.83 




 6 n/a 29.78 
 7 n/a 32.30 
LHA 3 256.77 62.01 
 4 920.10 50.96 




 6 n/a 26.45 
 7 n/a 28.38 
LHE 3 118.52 59.52 
 4 455.88 58.62 




 6 n/a 31.23 
 7 n/a 27.89 
Table 3-4 Summary of the rate at which BoNTA, BoNTE, LHA and LHE cause vesicle leakage 
over a pH range of pH 7- pH 3 
 
3.4.3.4 Removing the HC domain of BoNT effects the proteins ability to cause vesicle 
leakage at 20°C, 30°C and 40°C 
 
  By controlling the temperature at which we assessed both BoNT and LHN induced 
vesicle leakage we have attempted to gain insight into how removing the HC domain of 
BoNT effects protein-vesicle interactions. Vesicle leakage induced by the addition of 0.1µM 
BoNTA, BoNTE, LHA and LHE to lipid vesicles at 20°C, 30°C and 40°C respectively elucidated 




 BoNTA induced a faster rate of vesicle leakage than LHA at 20°C, 30°C and 40°C 
respectively. The most remarkable difference can been seen at 20°C where the percentage 
vesicle leakage seen after 1000 seconds has been reduced from 47.18% to 18.22%, 
demonstrating the importance of the HC domain to vesicle leakage at 20°C. At 30°C the 
removal of BoNTA’s HC domain reduces the proteins ability to induce vesicle leakage 
demonstrated by an increase in T50% time from 304.17 (BoNTA) to 877.49 seconds (LHA). 
 
 Variation in the rate at which serotype E molecules (BoNTE and LHE) induced vesicle 
leakage at 20°C, 30°C and 40°C was not as pronounced as seen for serotype A (BoNTA and 
LHA). In stark contrast to serotype A proteins, the vesicle leakage exhibited by both 
serotype E proteins at 20°C was similar, demonstrated by T50% values of 632.89 and 613.11 
seconds for BoNTE and LHE respectively. The most notable difference between BoNTE and 
LHE induced vesicle leakage was at 30°C where LHE has a slower rate of vesicle leakage 






Figure 3-25 Removing the HC domain of BoNT serotypes A and E affects the rate at which 
the proteins cause vesicle leakage.  
Vesicle leakage measured over a time course of 1000 seconds following the addition of 
0.1µM BoNT and LHN serotypes A and E respectively (pH4). (A) Vesicle leakage induced by 
0.1µM BoNTA at 40, 30 and 20°C respectively (n=3) (B) Vesicle leakage induced by 0.1µM 
LHA at 40, 30 and 20°C respectively (n=3) (C) Vesicle leakage induced by 0.1µM BoNTE at 40, 







leakage at 1000 
seconds 
BoNTA 20°C n/a 47.18 
 30°C 304.17 64.94 
 40°C 248.81 49.42 
BoNTE 20°C 632.89 64.22 
 30°C 248.51 65.04 
 40°C 194.58 48.57 
LHA 20°C n/a 18.22 
 30°C 877.49 53.40 
 40°C 466.40 49.74 
LHE 20°C 613.11 65.59 
 30°C 373.98 63.93 
 40°C 187.22 49.74 
Table 3-5 Summary of the rate at which BoNTA, BoNTE, LHA and LHE cause vesicle leakage 





 In the previous chapter (3.3) an assay was set up which was expected, based on 
correlation with literature (Galloux et al., 2008; Lai et al., 2010), to possess the ability to 
determine BoNT induced pore formation in phospholipid membranes. Here we evaluated 
the assay by testing whether proteins with no known pore forming ability (negative control 
proteins) disrupted dye loaded vesicles at acidic pH. Following this, the potential of 
endonegative versions of BoNTA and BoNTE to cause vesicle leakage was compared to that 
of LHA and LHE molecules in an attempt to assess the effect of removing the receptor 
binding domain (HC domain) on pore formation.  
 
3.4.4.1 All proteins interacted with DOPC:DOPG phospholipid vesicles at acidic pH 
 
In order to determine whether this vesicle leakage assay was an effective method 
of measuring pore formation in liposomes, a known pore forming peptide and three 
proteins with no known pore forming ability, were assessed for vesicle leakage at pH7 and 
pH4. GALA, a peptide reported to form pores in lipid vesicles at low pH (Nicol et al., 1999) 
was used to demonstrate that pH sensitive vesicle leakage could be achieved in accordance 
with literature. A 1µM concentration of GALA showed vesicle leakage at pH4 but not at 
pH7, this confirms that the assay used is capable of detecting pH sensitive peptide-
membrane interactions that have been reported to be evidence of pore formation. 
 
 BSA, Transferrin and the light chain domain of BoNTA (LCA) have no recognized 
ability to form pores; yet all three proteins induced vesicle leakage under acidic conditions 
(Figure 3-22). If proteins with no known pore forming ability are capable of causing vesicle 
leakage, then it is likely that the assay (at least under these conditions) cannot distinguish 
between bona fide pH regulated protein pore formation and a more general disruption of 
phospholipid membranes.  
 
Acidic pH does not appear to destabilize phospholipid vesicles (Figure 3-22) (Lin et 
al., 2012), this suggests that any vesicle leakage that occurs at low pH does so via vesicle-
protein interactions. If vesicle leakage does not occur as a direct result of a proteins known 
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pore forming ability, it must be due to non-specific vesicle-protein interactions. At acidic pH 
the charge presented by free electron pairs present on amino acid side chains will become 
neutralized via protonation. This will reduce the solubility of the protein and concurrently 
increase its lipophilicity which in turn may be responsible for an increase in protein-vesicle 
interaction and consequently vesicle leakage. 
 The lack of protein controls for low pH induced vesicle leakage in literature has 
been confirmed through correspondence with a respective author (Lai et al., 2010). This 
suggests that many vesicle leakage assays reported in literature may also report a more 
general lipophilicity of proteins at acidic pH rather than a specific pore forming activity of 
specialized proteins. This does not necessarily mean that pore formation does not occur, 
but suggests that some vesicle leakage assays may not report pore formation in isolation. 
One published example of a well controlled vesicle leakage assay, set up to report BoNT 
pore formation, showed the heavy chain of BoNTA to induce the release of K
+ ions from 
vesicles composed of phosphatidyl choline and phosphatidyl glycerol where the LC domain 
(negative protein control) did not (Shone et al., 1987).  
 
3.4.4.2 A comparison between BoNTA and BoNTE vesicle interaction 
 
Given that, in our assay, vesicle leakage was stimulated by proteins with no known 
pore forming ability, protein induced vesicle leakage in this assay could not be assumed to 
measure pore formation. Rather it represented protein interaction with a phospholipid 
membrane which may or may not have included a protein lined pore component. Here I 
discuss the effect of endonegative BoNT molecules (serotypes A and E) on phospholipid 
vesicles in order to further investigate their general interactions with membranes. 
 
A comparison of the ability of BoNT serotypes A and E to cause vesicle leakage was 
conducted to identify whether BoNTE’s faster rate of translocation (Kumaran et al., 2009) 
translated into a faster rate of vesicle leakage. BoNTE causes vesicle leakage at a faster rate 
in comparison to BoNTA over almost all of the conditions tested. The most striking 
comparison between the two molecules was seen at 0.01µM, pH 5 and 20°C where BoNTE’s 
faster rate of vesicle leakage suggested that it possesses structural qualities which allow it 
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to associate with vesicles in a way which is more energetically favorable than BoNTA. 
BoNTE’s propensity to induce a faster rate of vesicle leakage at 20°C may be suggestive of 
structural properties needed to sustain toxin activity in cold blooded animals such as fish 
(Piazza et al., 2011).  
 
 
Figure 3-26 BoNTE induces a faster rate of vesicle leakage than BoNTA at 20°C and pH5  
(A) and (B) The crystal structure of Botulinum neurotoxin serotype A (3BTA) and E (3FFZ) 
respectively (Kumaran et al., 2009; Lacy et al., 1998); the receptor binding domain (HC 
domain) is displayed in red, the translocation domain (HN domain) in green and the catalytic 
domain (Light chain, LC domain) in blue. (C) Vesicle leakage induced by BoNTA (red) and 
BoNTE (blue) at 20°C over 1000s (pH4). (D) Vesicle leakage induced by BoNTA (red) and 
BoNTE (blue) at pH5 over 1000s. 
  
3.4.4.3 Vesicle leakage is induced by BoNT and LHN molecules 
 
As discussed earlier, by removing the HC domain of BoNT’s we create LHN proteins. 
LHN proteins are known to form pores in Neuro2A cell membranes (Fischer and Montal, 




responsible for the translocation function of BoNT. As a result of this it is hypothesised that 
they could be considered a good and safe model to investigate BoNT pore formation. 
 
Here we compare and contrast vesicle leakage caused by BoNT and LHN proteins of 
the same serotype, thus elucidating the effect of removing the HC domain on BoNT-vesicle 
interaction.  
 
Removing the HC domain of BoNTA affects the proteins ability to cause vesicle 
leakage in three ways; (1) the rate of vesicle leakage is reduced at high concentrations; (2) 
the rate of vesicle leakage is reduced at pH4; (3) little to no vesicle leakage occurs at 20°C. 
The third factor is by far the most pronounced; if vesicle leakage is drastically reduced by 
removing the HC domain of BoNTA this may be evidence that the protein adopts a stable 
conformation that has less propensity to be lipophilic. Whether or not this change in the 
proteins lipophilicity identifies properties of LHA that would be relevant in a physiological 
environment is unclear as the conditions under which this change has been observed are 
not physiological. Further analysis of the protein by Circular dichroism at various pH levels 
and temperatures would allow further analysis of this point. 
 
Removing the receptor binding domain of BoNTE has a very minimal effect on the 
proteins propensity to cause vesicle leakage. The concentration and pH range at which LHE 
is able to induce vesicle leakage is very similar to that of BoNTE suggesting that the proteins 
behave very similarly in interaction with lipid membranes under the conditions tested. The 
only notable difference between BoNTE and LHE induced vesicle leakage occurs at 30°C for a 
reason not apparent in these experiments. Unlike removing the HC domain of BoNTA, 
removing the HC domain of BoNTE does not seem to inhibit the protein’s ability to cause 
vesicle leakage at 20°C, why this may be the case is not clear but could be related to a 




 Proteins with known and no-known pore forming ability have been assessed for 
their potential to cause vesicle leakage at pH4 and pH7. This has revealed that this vesicle 
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leakage assay is not capable of distinguishing between pore forming and non-pore forming 
proteins at acidic pH. Consequently, based on these results, we cannot conclude that BoNT 
induced vesicle leakage is as a direct result of BoNT pore formation and HN domain 
membrane insertion.  
  
 Removing the receptor binding domain (HC domain) of BoNT serotype A has a more 
pronounced effect on the rate at which it is capable of causing vesicle leakage than 
removing the HC domain of BoNTE. Removing the HC domain of BoNTA reduces the proteins 
potential to cause vesicle leakage over a range of concentrations, pH values and 
temperatures; the most remarkable of these is LHA’s lack of ability to cause vesicle leakage 
at 20°C suggesting that LHA possesses different structural characteristics in comparison to 
BoNTA. Concurrently, the removal of BoNTE’s HC domain has little effect on the proteins 













3.5 The serotype specific interaction of LHN proteins with phospholipid membranes. 
 
3.5.1 Introduction  
 
Botulinum neurotoxins have evolved simultaneously in a range of genetically 
diverse clostridia species. This evolution has resulted in seven genetically and functionally 
distinct serotypes (serotypes A-H) and an unknown number of sub serotypes. How these 
seven serotypes are functionally distinct is still an area of great potential discovery (Figure 
3-27). 
 
 Current evidence for sterotypically distinct BoNT function can be broken down into 
four areas; receptor binding, pore formation, LC domain translocation and SNARE cleavage 
(Chapter 1, Introduction). Here we attempt to investigate the relationship between 




Figure 3-27 Comparison of the translated genetic sequences of BoNT serotypes A-G.  
Shown above is a neighbor-joining alignment of the nucleotide coding regions of the seven 
serotypes of BoNT (A through G).  
 
3.5.1.1 Aim  
 
 In the previous chapter non-specific protein-vesicle interactions were determined 
to disrupt phospholipid vesicles at acidic pH. In order to investigate whether at least some 
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component of the observed vesicle leakage can be attributed to protein pore formation in 
vesicle membranes, an attempt has been made to visualise vesicle-protein interaction 
through electron-microscopy.  
 
 Whether or not LHN proteins form pores in lipid vesicles, the rate at which they 
disrupt lipid vesicles over various concentration, pH and temperature conditions is evidence 
of the proteins lipophilicity and potentially their propensity to insert into vesicle 
membranes. For this reason, five different serotypes of LHN (serotypes A-E) were compared 
for their potential to cause vesicle leakage under various concentrations, pH levels and 
temperatures. Furthermore, the effect of reducing the disulphide bond between the HN and 
LC domains of LHN molecules (serotypes A-D) was examined to see whether removing this 








3.5.2.1 Electron microscopy 
 
 50µl of 1mg/ml protein solution was mixed with 100µl of phospholipid vesicles for 
one hour in low pH buffer to mirror conditions seen during vesicle leakage assays (25mM 
Tris, 50mM NaCl, pH4) at room temperature. The samples were then loaded onto glow 
discharged carbon-coated copper grids and negative staining with 0.75% (w/v) Uranyl 
Formate. Micrographs were recorded at a nominal magnification of 50,000x on a Philips 
CM100 electron microscope operating at 100kV. 
 
3.5.2.2 Vesicle creation  
 
See section 3.4.2.1 
3.5.2.3 Vesicle concentration/calibration assay 
 
See section 3.4.2.2 
3.5.2.4 Vesicle leakage assay 
 
See section 3.4.2.3. 
3.5.2.5 Data analysis 
 





3.5.3.1 Using electron microscopy to visualize pore formation 
 
 To qualify whether BoNTA, LHA, GALA or the light chain domain of BoNT serotype A 
(LCA) form pores in phospholipid vesicles, election microscopy was used to directly visualise 
protein-vesicle interactions. The stain used for electron microscopy (Uranyl Formate) binds 
to proteins but not to phospholipids allowing the distinction to be made between protein 
and lipid structures; consequently proteinous patches appear dark and vesicle membranes 
appear transparent (Lai et al., 1984). 
 
 In the absence of protein, no intact vesicles were visualised (Figure 3-28, A). This is 
the expected result because the stain does not bind to phospholipids. Pre-incubation of 
vesicles with LHA, LCA or BoNTA revealed intact vesicle structures; this visualisation was not 
apparent following pre-incubation with the GALA pore forming peptide or with reduced LHA 
protein. 
 
 Following pre-incubation with BoNTA and LHA (proteins with known pore forming 
activity), vesicles had a dark coating and small round dark patches (Figure 3-28 B, C and D). 
In contrast, vesicles pre-incubated with LCA had a dark proteinous coating, but no small 
dark circular patches Figure 3-29, C). This is suggestive of a difference between the protein-
vesicle interactions of known pore forming proteins and non-pore forming proteins.  
 





Figure 3-28 Electron micrographs of vesicle-protein interactions.  
DOPC/DOPG vesicle membranes were incubated with assay buffer, LHA and BoNTA 
respectively at pH4. (A) Electron micrograph depicting the effect of assay buffer on vesicles. 
(B) Electron micrograph of the effect of 1µM LHA on lipid vesicles after a ten minute 
incubation. (C and D) Electron micrograph of the effect of 1µM BoNTA on lipid vesicles after 
a ten minute incubation. Dark patches attributed to protein aggregation have been 






Figure 3-29 Electron micrographs of vesicle-protein interactions.  
DOPC/DOPG vesicle membranes were incubated with reduced LHA, GALA and LCA 
respectively at pH4. (A) Electron micrograph of the effect of 1 µM reduced LHA on 
phospholipid vesicles. (B) Electron micrograph of the effect of 1 µM GALA on phospholipid 





3.5.3.2 Concentration dependent/ serotype specific vesicle leakage 
 
 The vesicle leakage assay was used as a tool to define serotype specific differences 
in the rate at which LHN proteins disrupt vesicular membranes. Here the concentration 
dependency of vesicle-LHN interaction is assessed for LHN serotypes A-E (all experiments 
were completed at pH4).  
 
 After 1000 seconds LHA concentrations of 1, 0.1, and 0.001µM caused vesicle 
leakage of 64.36, 63.25 and 43.72% respectively at pH4. No other concentrations of LHA 
tested showed vesicle leakage. 1µM LHA demonstrated a time to 50% vesicle leakage 
(T50%) value of 330.86 seconds, consequently LHA showed the slowest rate of vesicle 
leakage at a 1µM concentration (Figure 3-30, A) (pH4).   
 
LHB is distinctive in vesicle leakage assays as it was the only serotype to induce no 
vesicle leakage at 0.01µM (Figure 3-30, B), pH4. After 1000 seconds LHB concentrations of 1 
and 0.1µM caused vesicle leakage of 66.13 and 56.86% respectively. LHB demonstrated a 
T50% time of 199.26 and 462.92 seconds at concentrations of 1 and 0.1µM respectively 
demonstrating the second fastest rate of vesicle leakage at 1µM. 
 
When tested at a concentration of 0.001µM, LHC showed the highest level of vesicle 
leakage after 1000 seconds (42.51%) (Figure 3-30, C). LHC demonstrates a T50% time of 
228.31, 303.93 and 567.44 seconds at concentrations of 1, 0.1 and 0.01µM respectively. 
 
LHD displayed the highest rate of vesicle leakage at concentrations of 0.1 and 0.01 
µM respectively (Figure 3-30, D). After 1000 seconds LHD concentrations of 1, 0.1, 0.01, 
0.001µM caused vesicle leakage of 71.40, 65.96, 57.97 and 39.18% respectively. LHD 
demonstrated a T50% time of 209.40, 228.04 and 398.84 seconds at concentrations of 1, 
0.1 and 0.01µM respectively. 
 
LHE displayed the highest rate of vesicle leakage at 1µM (Figure 3-30, E). After 1000 
seconds LHE concentrations of 1, 0.1, 0.01, 0.001µM caused vesicle leakage of 68.60, 62.98, 
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54.47 and 40.01% respectively. LHE demonstrated a T50% time of 193.58, 329.38 and 





Figure 3-30 LHN serotypes A-E cause vesicle leakage in a concentration dependent 
manner. 
Vesicle leakage is measured over a time course of 1000 seconds at 37°C (pH4) (A) Vesicle 
leakage induced by 1, 0.1, 0.001 and 0.0001µM LHA respectively (n=3). (B) Vesicle leakage 
induced by 1, 0.1, 0.001 and 0.0001µM LHB respectively (n=3). (C) Vesicle leakage induced 
by 1, 0.1, 0.001 and 0.0001µM LHC respectively (n=3). (D) Vesicle leakage induced by 1, 0.1, 
0.001 and 0.0001µM LHD respectively (n=3). (E) Vesicle leakage induced by 1, 0.1, 0.001 and 








leakage at 1000 
seconds 
LHA 1 330.86 64.36 
 0.1 394.24 63.25 




LHB 1 199.26 66.13 
 0.1 462.928 56.86 




LHC 1 228.31 66.98 
 0.1 303.93 64.03 




LHD 1 209.40 71.40 
 0.1 228.04 65.96 




LHE 1 193.58 68.60 
 0.1 329.38 62.98 




Table 3-6 Summary of the rate at which LHN seortypes A-E cause vesicle leakage over a 
concentration range of 1 to 0.001µM. 
 
3.5.3.3 pH dependent / serotype specific vesicle leakage 
 
It has long been established that acidification of the endosomal compartment is 
essential to the action of Botulinum neurotoxins (Montecucco et al., 1994). Here we 
demonstrate how LHN serotypes A-E interact with vesicular membranes under different pH 
conditions in an attempt to provide insight into the lipophilicity of various LHN serotypes 
over a range of pH conditions.  As LHN molecules (serotypes A-E) were shown to cause 
vesicle leakage in a concentration dependent manner, it has been necessary to complete 
the analysis of pH dependent vesicle leakage using concentrations of LHN molecules which 




 A 0.05µM concentration of LHA caused vesicle leakage at pH3 and pH4 respectively.  
The rate at which LHA caused vesicle leakage at pH3 was approximately 3.5x greater than at 
pH4 (T50% values of 256.77 and 920.10 seconds respectively). 
 
A 0.1µM concentration of LHB caused vesicle leakage at pH3, pH4 and pH5 
respectively. The rate at which LHB caused vesicle leakage at pH3 was approximately 2x 
greater than at pH4 (T50% values of 457.88 and 901.35 seconds respectively). In 
comparison to other serotypes, LHB demonstrated the lowest rate of vesicle leakage at pH3 
even though it is tested at the highest concentration. 
 
A 0.01µM concentration of LHC caused vesicle leakage at pH3 and pH4 respectively.  
The rate at which LHC caused vesicle leakage at pH3 was approximately 0.75x greater than 
at pH4 (T50% values of 513.30 and 682.36 seconds respectively). LHC showed the lowest 
increase in rate between pH4 and pH3 of all serotypes. 
 
A 0.01µM concentration of LHD caused vesicle leakage at pH3, pH4 and pH5 
respectively.  The rate at which LHD caused vesicle leakage at pH3 was approximately 1.3x 
greater than at pH4 (T50% values of 294.00 and 379.01 seconds respectively) and 
approximately 3.2x greater than at pH5 (T50% value of 953.25 seconds respectively). LHD 
demonstrated the highest rate of vesicle leakage seen at pH5 even though it was tested at 
the lowest concentration. 
 
A 0.05µM concentration of LHE caused vesicle leakage at pH3, pH4 and pH5 
respectively.  The rate at which LHE caused vesicle leakage at pH3 was approximately 3.8x 
greater than at pH4 (T50% values of 455.88 and 118.52 seconds respectively). LHE had the 
fastest rate of vesicle leakage at pH3 although it was tested at a higher concentration than 









Figure 3-31 LHN serotypes A-E cause vesicle leakage in a pH dependent manner at pH 3-7.  
Vesicle leakage is measured over a time course of 1000 seconds at 37°C following the 
addition of 0.05µM LHA, 0.1µM LHB, 0.01µM LHC, 0.01µM LHD  and 0.05µM LHE respectively. 
(A) Vesicle leakage induced 0.05µM LHA at pH 3, 4, 5, 6 and 7 respectively (n=3). (B) Vesicle 
leakage induced by 0.1µM LHB at pH 3, 4, 5, 6 and 7 respectively (n=3). (C) Vesicle leakage 
induced by 0.01µM LHC at pH 3, 4, 5, 6 and 7 respectively (n=3). (D) Vesicle leakage induced 
by 0.01µM LHD at pH 3, 4, 5, 6 and 7 respectively (n=3). (E) Vesicle leakage induced by 







 pH T50% 
(Seconds) 
% Vesicle 
leakage at 1000 
seconds 
LHA 3 256.77 62.01 




 6 n/a 26.45 
 7 n/a 28.38 
LHB 3 457.88 61.04 




 6 n/a 30.45 
 7 n/a 32.35 
LHC 3 513.30 55.64 




 6 n/a 25.74 
 7 n/a 27.7 
LHD 3 294.00 59.30 




 6 n/a 33.25 
 7 n/a 31.47 
LHE 3 118.52 59.52 




 6 n/a 31.23 
 7 n/a 27.89 
Table 3-7 Summary of the rate at which LHN seortypes A-E cause vesicle leakage over a pH 
range of pH7-pH3. 
 
3.5.3.4 The serotype specific temperature dependence of LHN induced vesicle leakage 
 
Botulinum neurotoxins are known to intoxicate cold and warm blooded organisms. 
The temperature dependent nature of a serotype’s interaction with lipid membranes may 
provide evidence of why different serotypes induce a toxic effect at different temperatures. 
All experiments were completed using an LHN concentration of 0.1µM at pH4, this allows 
direct comparisons to be drawn between the rate at which all five serotypes of LHN cause 




LHA caused little or no vesicle leakage at 20°C in stark contrast with all other 
serotypes (18.22% vesicle leakage after 1000 seconds). However, LHA did induce vesicle 
leakage at 40°C and 30°C with T50% values of 466.40 and 877.49 seconds respectively. 
Increasing the temperature from 30°C to 40°C caused an approximate 1.8x increase in the 
rate of LHA induced vesicle leakage. 
 
LHB induced vesicle leakage at 20°C, 30°C and 40°C, this caused vesicle leakage of 
38.72, 53.73 and 46.38% respectively after 1000 seconds. Due to this comparatively low 
level of vesicle leakage, LHB only presented a T50% value at 30°C (761.48 seconds). 
 
Vesicle leakage occurred at 20°C, 30°C and 40°C following the introduction of 
0.1µM LHC to lipid vesicles, showing T50% values of 961.74, 448.12 and 246.85 respectively. 
The rate of vesicle leakage induced by LHA increased by approximately 2.2x after increasing 
the temperature from 20°C to 30°C and approximately 1.8x after increasing the 
temperature from 30°C to 40°C. 
 
LHD caused a higher rate of vesicle leakage than LHN serotypes A, B, C and E at 20°C, 
30°C and 40°C. Increasing the temperature of the assay from 20°C to 30°C increased the 
rate of vesicle leakage by approximately 1.2x, further increasing the temperature from 30°C 
to 40°C caused a further 1.7x increase in the rate of vesicle leakage.   
 
 LHE caused a higher rate of vesicle leakage than LHN serotype A, B and C at 20°C, 
30°C and 40°C. Increasing the temperature of the assay from 20°C to 30°C increased the 
rate of vesicle leakage by approximately 1.6x, further increasing the temperature from 30°C 
to 40°C caused a further 2x increase in the rate of vesicle leakage.  
 
The stability of lipid vesicles at 20°C, 30°C and 40°C was assessed through 
measuring spontaneous vesicle leakage under assay conditions (Figure 3-32, C). The lowest 
level of spontaneous vesicle leakage was seen at 20°C suggesting that vesicles show a 




Figure 3-32 LHN proteins (serotypes A-E) cause vesicle leakage in a temperature 
dependent manner.  
Vesicle leakage is measured over a time course of 1000 seconds following the addition of 
0.1µM LHN serotypes A to E respectively (pH4). (A) Vesicle leakage induced by 0.1µM LHA at 
40, 30 and 20°C respectively (n=3) (B) Vesicle leakage induced by 0.1µM LHB at 40, 30 and 
20°C respectively (n=3) (C) Vesicle leakage induced by 0.1µM LHC at 40, 30 and 20°C 
respectively (n=3) (D) Vesicle leakage induced by 0.1µM LHD at 40, 30 and 20°C respectively 
(n=3). (E) Vesicle leakage induced by 0.1µM LHE at 40, 30 and 20°C respectively (n=3). (F) 












leakage at 1000 
seconds 
LHA 20°C n/a 18.22 
 30°C 877.49 53.40 
 40°C 466.40 49.74 
LHB 20°C n/a 38.72 
 30°C 761.48 53.73 
 40°C n/a 46.38 
LHC 20°C 961.74 52.43 
 30°C 448.12 66.26 
 40°C 246.85 47.52 
LHD 20°C 260.70 69.35 
 30°C 204.04 65.59 
 40°C 115.58 49.41 
LHE 20°C 613.11 65.59 
 30°C 373.98 63.93 
 40°C 187.22 49.74 
Table 3-8 Summary of the rate at which LHN serotypes A-E cause vesicle leakage at 20°C, 
30°C and 40°C. 
 
3.5.3.5 LHN induced vesicle leakage in reducing and non-reducing conditions 
 
Vesicle leakage induced by a 1µM concentration of LHN serotypes A-D has been 
assessed under non-reducing and reducing conditions (±10mM DTT) respectively.  This has 
been completed to assess whether reducing the di-sulphide bond present between the HN 
domain and LC domain of LHN proteins affects the way in which the proteinous domains of 
LHN interact with phospholipid vesicles.  
 
 Two serotypes of LHN interact differently with phospholipid vesicles under 
reducing and non-reducing conditions respectively, namely LHA and LHC. Under reducing 
conditions, LHA and LHC caused vesicle leakage at a slightly faster rate than under non-
reducing conditions (T50% values of 361.21 and 281.57 in comparison to 476.55 and 363.59 
seconds, respectively).  
 
Vesicle leakage induced through the interaction of LHB and LHD with phospholipid 
vesicles did not markedly change between reducing and non-reducing conditions (T50% 
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values for reducing 240.15 and 185.02 and non-reducing conditions 222.22 and 147.04 
seconds respectively). Furthermore, lipid vesicles were found not to be destabilised in the 







Figure 3-33 LHN proteins cause vesicle leakage under reducing conditions.  
Vesicle leakage is measured over a time course of 1000 seconds following the addition of 
1µM LHN serotypes A to D respectively (pH4). (A) Vesicle leakage induced by 1µM LHA with 
and without 10mM DTT respectively (n=3) (B) Vesicle leakage induced by 1µM LHB with and 
without 10mM DTT respectively (n=3) (C) Vesicle leakage induced by 1µM LHC with and 
without 10mM DTT respectively (n=3) (D) Vesicle leakage induced by 1µM LHD with and 
without 10mM DTT respectively (n=3) (E) Vesicle leakage induced by assay buffer with and 






  T50% 
(Seconds) 
% Vesicle 
leakage at 1000 
seconds 
LHA +DTT 361.21 60.79 
 n/a 476.55 60.83 
LHB +DTT 240.15 60.13 
 n/a 222.22 62.38 
LHC +DTT 281.57 61.27 
 n/a 363.59 
 
61.50 
LHD +DTT 185.02 64.22 
 n/a 147.94 67.88 
Control +DTT n/a 26.45 
 n/a n/a 24.23 
Table 3-9 Summary of the rate at which LHN serotype A-D cause vesicle leakage in 






 Here we attempt to measure serotype specific differences in the way in which LHN 
molecules interact with lipid vesicles, through this we attempt to determine serotype 
specific differences in LHN pore formation. Firstly, electron microscopy was used to directly 
visualise whether BoNT or LHN pores were formed in vesicle membranes. Secondly, vesicle 
leakage was used to analyse serotype specific differences in the way LHN molecules interact 
with vesicular membranes through varying the concentration, pH and temperature at which 
interactions occur. Thirdly, we analysed the effect of reducing the disulphide bond between 
the HN and LC domains of LHN molecules on vesicle leakage (serotypes A-D). 
 
3.5.4.1 Electron microscopic analysis of protein-vesicle interactions 
In the previous chapter, it was discovered that vesicle leakage could not 
conclusively report protein or peptide pore formation but instead reports the more general 
destabilization of phospholipid membranes by proteins. Here we assess whether or not we 
are able to visualize a BoNT or LHN pore forming in lipid vesicles using electron microscopy. 
The effect of known pore forming proteins and peptides, such as endonegative BoNTA, LHA, 
and GALA, were compared to the effect of a protein with no known non-pore forming 
ability (light chain domain of BoNTA (LCA) at pH4.   
 
Literature examples of protein pores formed by toxins in lipid vesicles (Diphtheria 
toxin and Hemolysin E toxin, (Figure 3-34, A and B respectively)), demonstrate that the 
negative stain (Uranly Formate), stains protein molecules and leaves phospholipids 
translucent (Lai et al., 1984). Whilst both have been determined to show evidence of 
protein pore formation in lipid vesicles only the Hemolysin shows clear and definable pores 
which are thought to consist of eight 34KDa subunits (Wallace et al., 2000). Electron 
microscopic analysis of the interaction between BoNT and LHN proteins with lipid vesicles 
was completed at pH4 (Figure 3-28, B, C and D); both BoNT and LHN proteins line the 
outside of lipid vesicles in a manner similar to diphtheria toxin, suggesting that BoNT and 
LHN molecules have affinity for a lipid environment at acidic pH. Dark circles which appear 
on the membrane surface may represent pores in vesicle membranes but are most likely 
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protein aggregation. There is no clear and definable pore like structure evident following 
vesicle incubation with either BoNT or LHN. 
 
 
Figure 3-34 Diphtheria toxin and Hemolysin E toxin form pores in vesicle membranes 
(A) Electron microscopic analysis of the interaction between Diphtheria toxin with 
phospholipid membranes at acidic pH (B) Electron microscopic analysis of the interaction 
between Hemolysin E toxin and phospholipid membranes at neutral pH  (Lai et al., 1984; 
Wallace et al., 2000) 
 
Liposomes were found not to be visible under the conditions of electron 
microscopy without the presence of protein in solution (Figure 3-29, A). This casts doubt 
over the structural integrity of the liposomes and could explain why proteins with no 
known pore forming ability have been seen to cause vesicle leakage (section 3.4.3.1). 
Concurrently, a protein control with no known pore forming activity (LCA) appears to line 
the outside of and stabilize phospholipid vesicles in a manner consistent with BoNT and LHN 
proteins (Figure 3-28, C). Unlike BoNT and LHN proteins, LCA does not show dark circles on 
the surface of vesicles. This demonstrates that a perceived non-pore forming protein shows 
affinity for phospholipid vesicles at acidic pH; this affinity may be sufficient to induce vesicle 
leakage without the formation of a pore if the liposome is considered structurally unsound.  
 
3.5.4.2 LHN serotypes A-E disrupt vesicle membranes in a serotype specific fashion 
 
As electron microscopic analysis has not validated the presence of specific pore 
formation in lipid vesicles, it is not possible to derive evidence of LHN pore formation from 
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this vesicle leakage assay. However, we can study the conditions under which LHN serotypes 
A-E become lipophilic and thus the conditions under which they would be most likely to 
form pores. 
 
LHA is evidently the least lipophilic of the LHN serotypes tested. This is 
demonstrated comparatively by its low rate of vesicle leakage at high concentration, its 
inability to cause vesicle leakage at pH5 and its near inability to cause vesicle leakage at 
20°C. This apparent lack of lipophilicity may suggest that the protein is more stable at low 
pH, further analysis through circular dichroism may elucidate why LHA is more stable and 
less lipophilic in these conditions. 
 
LHB concentrations lower than 0.01µM fail to induce vesicle leakage; consequently 
LHB demonstrates the highest level of concentration dependency of all serotypes. This may 
suggest that LHB has a tendency to aggregate in a multimeric form effectively decreasing 
the number of free molecules in solution and thus the probability of disrupting lipid 
vesicles. LHB may form a multimeric conformation similar to BoNTB’s trimeric pore forming 
structure (Sun et al., 2011).  
 
 LHC demonstrates the fastest rate of vesicle leakage at a concentration of 0.001µM 
showing that in comparison to other serotypes it only needs a very low concentration to 
initiate vesicle leakage. Like LHA, LHC does not disrupt vesicle membranes at pH5 and shows 
a exceptionally temperature dependant form of vesicle leakage. This suggests that it takes a 
very acidic pH and a high temperature for LHC to adopt a lipophilic conformation. This may 
mean that the protein is less hydrophobic than other LHN proteins.  
 
LHD displays the fastest rate of vesicle leakage at concentrations of 0.1µM and 
0.01µM respectively. Serotype D also shows the highest rate of vesicle leakage at pH5 and 
at 20°C, 30°C and 40°C respectively. As serotype D shows the highest rate of vesicle leakage 
both at pH5 and 20°C this suggests that it requires less energy to adopt a conformation 
capable of permeabilising membranes. The stoichiometry with which LHD permeabilises 
membranes may be simpler than the multimer proposed for LHB allowing this serotype to 
form pores over a wider range of concentrations.  The wide range of conditions over which 
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LHD is capable of causing liposome permeabilisation may be related to why BoNTD is such a 
quick acting toxin in rats and mice in comparison to other serotypes (Eleopra et al., 2013). 
The rapid rate at which LHD is able to cause vesicle leakage over an array of concentrations 
may suggest that the structure of LHD is the most hydrophobic of the serotypes tested. 
 
As well as demonstrating the highest rate of vesicle leakage at 1µM, LHE 
demonstrates the greatest increase in the rate of vesicle leakage seen when decreasing the 
extravesicular pH from pH4 to pH3 (a ~3.8x increase in rate of vesicle leakage). This 
suggests that LHE is affected greatly by a change in pH conditions and readily adopts a 
lipophilic structural organisation. This may be related to the fast rate of BoNTE 
translocation, thought to be brought about by the molecules readiness to adopt a 
multimeric pore like structure at pH5 in contrast to BoNTB which requires more acidic 
conditions (Sun et al., 2012). 
 
 As we have concluded that the lipophilicity of LHN molecules at acidic pH is 
responsible for the rate at which they cause vesicle leakage, a comparison between the 
surface charge of LHN proteins at low pH may be seen to correlate with the rate of vesicle 
leakage observed. However, there is a lack of sufficient structural information to draw such 
a comparison. 
 
3.5.4.3 Reducing the disulfide linkage between the heavy and light chain of LHN molecules 
 
Patch clamp experiments have shown BoNT and LHN to form pores in excised 
segments of cell membranes (see section 1.5.2.5). The pore formed was considered to be in 
a closed conformation if the LC domain occupied the pore and an open conformation if it 
did not (Fischer and Montal, 2007b). Reducing the disulphide bond connecting the LC and 
HN domains prior to pore formation has been shown to only allow the formation of open 
pores (Fischer and Montal, 2007a). To see whether we could detect evidence of the 
proposed closed (or blocked) and open pores in vesicular membranes, a comparison was 
made between vesicle leakage induced by LHN (serotypes A-D) with and without a reducing 
agent known to reduce the inter-domain disulphide bond (10mM DTT, see section 3.2.2.5) 




A small difference in the rate of vesicle leakage achieved by LHA and LHC under 
reducing and non-reducing conditions was detectable. In both cases the rate of vesicle 
leakage was seen to be slightly higher under reducing conditions suggesting that it may be 
possible to see blocked and open pore formations though a change in the rate of vesicle 
leakage.  
 
LHB and LHD do not show any significant difference in the rate at which they cause 
vesicle leakage in reducing and non-reducing conditions. Clarity on this issue might be 
provided by analyzing the rates of LHN serotypes A-D over a range of concentrations under 





 Firstly, the interaction of BoNT and LHN proteins with lipid vesicles at low pH was 
visualized using electron microscopy. Analysis of these interactions did not show clear 
evidence of stable pores formed in lipid vesicles. However, all proteins incubated with 
vesicles at low pH (including LCA) showed a lipophilic affinity for the liposomes. This 
correlated well with our previous findings that all proteins tested caused dye leakage at 
acidic pH (Figure 3-22). 
 
 Secondly, the ability of LHN serotypes A, B, C, D and E to cause vesicle leakage was 
concentration, pH and temperature dependent. We conclude that serotype specific 
differences in ability to permeate phospholipid vesicles represents each serotypes 
propensity to adopt a lipophilic conformation, differences in this property must affect each 
HN domains pore formation activity.  
 
 Finally, it could not be concluded that differences demonstrated between vesicle 
leakage caused by reduced and non-reduced LHN proteins (serotypes A and C) was a result 





4 General Discussion 
  
 The Clostridium botulinum neurotoxin (BoNT) is a fascinating example of the 
specific and intricate nature in which toxins manipulate cellular function. The seven 
different serotypes of BoNT specifically target and enter the cholinergic neuromuscular 
synapse where they cause flaccid muscular paralysis (with great potency) through inhibiting 
the cells ability to perform exocytosis (Montal, 2010). This mechanism is thought to be 
dependent on BoNTs tri-modular domain structure which includes the following domains: 
receptor binding domain (HC), translocation domain (HN) and catalytic domain (LC). Much is 
known about the mechanism through which the HC domain binds with specificity to the pre-
synaptic terminal of the neuromuscular junction and the mechanism by which the LC 
domain cleaves SNARE proteins preventing exocytotic vesicular secretion but very little is 
known about the way in which the HN domain interacts with cellular membranes. 
 
 In this investigation we have set out to shed light on the most elusive mechanism of 
BoNT intoxication, namely, the serotype specific way in which the HN domain of BoNT 
interacts with cellular membranes. Through analyzing the expression, purification, cellular 
interaction and artificial membrane interaction of BoNTs and their LHN and HN derivatives 
we have been able to determine the physical properties of BoNT, LHN and HN molecules. 
 
4.1 LHD effects an increase in CHO-K1 cell intracellular Ca
2+ levels 
 
 The interaction of LHD with CHO-K1 cell membranes was determined through the 
protein’s ability to cause an influx of extracellular Ca2+ into CHO-K1 cells at high 
concentration (Figure 3-1). Reducing extracellular Ca2+ concentration reduces the LHD 
induced increase in intracellular Ca2+, suggesting that LHD was capable of facilitating the 
movement of Ca2+ from the extracellular to intracellular environment (Figure 3-2). Whilst it 
was hypothesized that this movement of Ca2+ may be as a result of a pore formed by LHD in 
the CHO-K1 cell membrane, the difficulty associated with reliably reproducing this response 
resulted in the eventual termination of this study. However, the idea that LHD may be 
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capable of forming a pore in cellular membranes at physiological pH and that BoNT and LHN 
pore formation is serotype specific was intriguing and required further investigation. 
 
4.2 LHN and HN domain physical properties were determined through expression and 
purification 
 
 In order to visualize if LHD might interact with cellular membranes in a different way 
to other serotypes and to elucidate the structure of its HN domain for the first time, LHD was 
expressed, purified and crystallized in an attempt to elucidate its three dimensional 
structure via X-ray crystallography (Figure 3-4). Unfortunately, these crystallization trials 
were unsuccessful which, in turn, lead to attempts to purify the HN domain of serotype D 
for inclusion in crystallization trials.  
 
 To isolate the HN domain of LHD, the LC and HN domains of LHD were successfully 
separated via affinity chromatography (Figure 3-6 and Figure 3-7). A detergent was 
required to separate the domains of LHD, confirming that the HN domain of LHD was 
hydrophobic. Due to a lack of reproducibility seen when attempting to isolate the HN 
domain of serotype D from its LHN construct, attempts were made to express and purify the 
HN domains of BoNT serotypes A and C. This lead to the successful expression and 
purification of HN serotype A (Figure 3-8) and the never before seen, successful expression 
and purification of HN serotype C (Figure 3-9). Notably, both serotypes required high levels 
of detergent to keep them soluble following expression and throughout the purification 
procedure, again displaying the hydrophobic nature of the HN domain. Due to time 
constraints the HN domains of BoNT serotypes A, C and D were not transferred into 
crystallization trials. 
 
4.3 Investigating the pore forming potential of BoNT and LHN proteins through vesicle 
leakage 
 
 In an attempt to evaluate the conditions under which BoNT and LHN form pores, a 
vesicle leakage assay was designed and developed (based on literature examples of vesicle 




 During the development of this vesicle leakage assay, it was determined that 
proteins with no known pore forming ability (e.g. BSA, LCA and Transferrin) were capable of 
inducing vesicle leakage at acidic but not neutral pH. Due to the surprising nature of these 
results, two authors who had studied the pore forming nature of BoNT using a vesicle 
leakage assay, were contacted to confirm whether or not they had also used non-pore 
forming (negative) protein controls (Lai et al., 2010). Upon confirmation that they had not, 
we began to question the ability of this vesicle leakage assay to determine protein pore 
formation at acidic pH. The ability of negative control proteins to cause vesicle leakage 
suggests that we do not specifically measure protein pore formation under these conditions 
but rather the lipophilicity of a protein at acidic pH. Specifically, as LCA molecules induced 
vesicle leakage at acidic but not neutral pH, it was thought that an increase in the 
molecules lipophilicity, known to be a result of protein refolding (Cai et al., 2006), was 
responsible for the molecules increased interaction with lipid vesicles.  
 
 To verify whether or not pore forming proteins were capable of forming pores in 
lipid vesicles, the interaction of BoNT and LHN toxins with lipid vesicles was investigated via 
electron microscopy. This analysis neither confirmed nor excluded the presence of a pore 
formed by either BoNT or LHN proteins in lipid vesicles (Figure 3-28 and Figure 3-29).  We 
therefore have to conclude that this vesicle leakage assay does not provide sufficient 
evidence to determine whether or not proteins or peptides form pores at acidic pH 
regardless of its similarity with published assays (Galloux et al., 2008; Lai et al., 2010). 
However, as the lipophilicity gained by BoNT domains at acidic pH has been determined to 
be important for the membrane interaction and pore formation of BoNT proteins 
(Colasante et al., 2013; Fischer et al., 2012), the rate at which vesicle leakage occurs in this 
assay may provide insight into the pore forming potential of the molecules tested.  
 
 It was demonstrated that removing the HC domain of BoNT serotypes A and E 
affects the rate at which they interact with phospholipid vesicles (Figure 3-23, Figure 3-24 
and Figure 3-25). In particular removing the HC domain of BoNTA inhibited its ability to 
permeate phospholipid vesicles at lower than physiological temperatures. It is plausible 
that removing the HC domain of BoNT will remove hydrophobic yet solvent exposed loops 
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located on the HCN subdomain (Muraro et al., 2009) causing a reduction in the molecule’s 
lipophilicity. However, why this affects the temperature at which the LHN molecule can 
induce vesicle leakage is not clear. Circular dichroism (CD) may be able to identify whether 
LHA adopts a significantly different structural arrangement over the temperature range 
tested (40°C-20°C), which in turn may identify why the lipophilicity of this molecule seemed 
to vary so markedly without the HC domain. (Lalli et al., 1999; Zhang et al., 2010). 
  
 As this vesicle leakage assay is comparable with others, published in literature, used 
to determine the conditions under which BoNTA and its derivatives form pores in vesicle 
membranes (e.g. (Galloux et al., 2008; Lai et al., 2010)), we may need to reinterpret some 
published examples of BoNT domain induced vesicle leakage. For example, in 2010 it was 
demonstrated that reducing the concentration of NaCl increased the rate at which vesicle 
leakage occurred following HN domain interaction with dye loaded lipid vesicles at pH4 (Lai 
et al., 2010). This was previously determined to be as a result of HN domain pore formation 
in lipid vesicles, however, given that negative protein controls were not run (e.g. BSA or 
Transferrin) we can only conclude that the HN domain possessed a higher lipophilicity at low 
NaCl concentration, suggesting that NaCl prevents protonation of the charged residues on 
the surface of the HN domain thus reducing the molecules lipophilicity. 
  
 LHN proteins were assessed to cause vesicle leakage in a serotype specific way 
which has the potential to highlight differences between the lipophilicity of LHN serotypes 
A-E under various conditions. Most remarkably LHD was shown to induce the fastest rate of 
vesicle leakage at pH5 (Figure 3-31) (the least acidic pH where vesicle leakage was 
detectable). Once again CD analysis of the change in LHN structure under various conditions 
may be instrumental in demonstrating why various serotypes of LHN molecules adopt more 
or less lipophilic arrangements under different conditions.  
 
 Finally, the effect of reducing the disulphide bond between the HN and LC domains 
of LHN molecules did not affect the rate of vesicle leakage determined. Therefore we could 
not conclude that either an open or closed pore was formed in lipid vesicles (Brunger et al., 




4.4 Further development of the vesicle leakage assay 
 
 It may yet be possible to develop a 96 well vesicle leakage assay that it is capable of 
determining whether or not a protein or peptide has the potential to form a pore in vesicle 
membranes at acidic pH. To facilitate this, we would need to develop a phospholipid 
mixture that created a more stable vesicle, not disrupted by non-specific protein-vesicle 
interactions. The inclusion of molecules such as Cholesterol, known to be essential to the 
integrity of plasma membrane microdomains and the composition of cellular vesicles, may 
serve to stabilize vesicle structure and thus prevent disruption of vesicle membranes by 
non-pore forming proteins (Goluszko and Nowicki, 2005).  
 
 The leakage of fluorescent dye from lipid vesicles has been shown to require a very 
high concentration of BoNT, LHN and HN protein respectively (Galloux et al., 2008; Lai et al., 
2010). In contrast the leakage of K+ ions from lipid vesicles has been shown to require a far 
lower concentration of BoNTA derivatives in order to determine pore formation (Shone et 
al., 1987). Furthermore, the assays ability to work at a lower concentration appears to allow 
it to distinguish between pore forming and non-pore forming proteins at acidic pH. 
Prospectively, it may be possible to load phospholipid vesicles with a high concentration of 
Ca2+ ions and monitor the BoNT induced leakage of Ca+2 into the extra-vesicular media 
through an increase in Ca2+ sensitive dye florescence.  
 
 Electrophysiological methods that have been used in the past to detect the 
conditions under which BoNT forms pores in cellular membranes (e.g. the patch clamp 
assay) still appear to be the most sensitive and accurate method for detecting BoNT, LHN 
and HN induced pore formation (Fischer and Montal, 2007b). Furthermore, the patch clamp 
assay is capable of determining both the open and closed HN pore conformations (Fischer et 
al., 2008b). If a vesicle leakage assay can be produced which can distinguish between pore 
forming and non-pore forming proteins, a direct comparison of BoNT and LHN induced pore 
formation (between the patch clamp and vesicle leakage assay) may enable a detailed and 
thorough analysis of vesicle leakage data. A 96 well vesicle leakage assay which has the 
capability of determining the formation of protein pores in lipid membranes would greatly 
advance the field of botulinum neurotoxin research and potentially allow the development 
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